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ABSTRACT 
 
 
Nicotine is considered a gateway drug for other drugs of abuse.  The majority of smokers 
that begin smoking in adolescence, continue into adulthood. Multiple factors have been 
linked with smoking initiation, including maternal smoking.  Drug exposure during 
pregnancy has long been suspected to exert deleterious effects on the fetal brain.  
Concurrent use of smoking and drinking alcohol throughout pregnancy is an all too 
frequent occurrence in the human population especially in disadvantaged and younger 
women. 
 
The present study investigated the potential contributing factors for the enhanced nicotine 
self-administration as seen in offspring with gestational exposure to nicotine and ethanol 
(Nic+EtOH).*  We focused on the mesocorticolimbic pathway, specifically the λ-
aminobutyric acid (GABA) and glutamate modulators of ventral tegmental area (VTA) 
dopamine (DA) neurons that project to the nucleus accumbens (NAcc). 
 
Our animal model of full gestational exposure to Nic+EtOH exposes the developing brain 
to both drugs throughout the entire 3 trimester human equivalent [i.e. gestational days 
(GD) 1-22 and postnatal days (PN) 2-12].  Using self-administration (SA), in vivo 
microdialysis, quantitative PCR, and western blot analysis, we investigated alterations in 
the VTA of offspring.  
 
We found that the enhancement of nicotine SA acquisition of offspring with gestational 
Nic+EtOH exposure is not due to changes in maternal-pup interactions.  The offspring 
with gestational Nic+EtOH exposure have a dramatic change in neurotransmitter release 
in response to 30µg i.v. nicotine; that displays a 75% increase of NAcc DA and a 50% 
reduction of VTA GABA release.  In comparison, pair-fed (PF) offspring show a 20% 
increase in NAcc DA and a 20% decrease in VTA GABA in response to nicotine.  
Nic+EtOH offspring also show sensitivity to n-methyl-d-aspartate (NMDA) in the VTA 
of offspring that results in a greater increase in NAcc DA and VTA glutamate release 
compared to the PF offspring.  The enhanced acquisition of nicotine SA seen in 
Nic+EtOH offspring can be reduced to PF levels with disruption to the 
mesocorticolimbic pathway by infusion of either a GABA agonist or a NMDA receptor 
antagonist into the VTA. 
 
These results correlate with the epidemiologic data that suggests that children with 
gestational drug exposure are more likely to smoke. The alteration of the 
mesocorticolimbic pathway present in the offspring with gestational Nic+EtOH exposure 
is present in both adult and adolescent offspring, suggesting that the neurochemical 
changes are long-lasting. 
 
*Matta SG, Elberger AJ (2007) Combined exposure to nicotine and ethanol throughout 
full gestation results in enhanced acquisition of nicotine self-administration in young 
adult rat offspring. Psychopharmacology (Berl) 193: 199-213 
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CHAPTER 1.    INTRODUCTION 
 
 
Nicotine is considered a gateway drug that may lead to other drugs of abuse, however 
unlike other drugs, nicotine use is less likely to decline later in life (Breslau and Peterson 
1996).  The age of smoking initiation is an important factor in determining dependence 
and methods of smoking cessation.  It has been reported that 90 percent of smokers tried 
their first cigarette before the age of 18 (Kandel et al. 2007) and those smokers are more 
probable to continue to smoke into adulthood (Colby et al. 2000).  Symptoms of nicotine 
dependence in adolescent smokers do not appear to have a minimum requirement of 
nicotine intake (DiFranza et al. 2002).  Adolescent smokers are less inclined to be daily 
smokers but when they are, they are likely to smoke less cigarettes compared to adult 
smokers (Colby et al. 2000).  The adolescents who experience symptoms of nicotine 
dependence do not represent a small portion of the population and for many those 
symptoms began before the onset of daily smoking (DiFranza et al. 2006). A study 
demonstrated that the rapid onset of symptoms for nicotine dependence, as seen in 
adolescent smokers, appears to represent a large portion of the population (DiFranza et 
al. 2000).  Nearly 21 percent of smokers display their first symptom of nicotine 
dependence within 3 months (Kandel et al. 2007).  Research has indicated two factors 
associated with continued smoking:  the number of cigarettes smoked and the sensation 
associated with the first cigarette (positive or negative experience) (Kandel et al. 2007). 
 
The use of tobacco products annually is reported by 26.5 percent of the population over 
the age of 12 according to the most recent data, with the highest reported use by young 
adults aged 18-25 years and 66.5 percent of these smokers reporting concurrent use of 
alcohol (Substance Abuse and Mental Health Services Administration 2012).  The 
availability of tobacco and alcohol because of legal sales allows both drugs to be seen as 
gateway drugs to other drugs of abuse (Grucza and Bierut 2006a; Myers and Kelly 2006). 
Sociocultural (i.e. family, peer, and economic) influences have been reported to influence 
smokers to drink alcohol, and those that drink alcohol to smoke (Bobo and Husten 2000).  
Smoking and drinking alcohol is an all too frequent occurrence especially in 
disadvantaged and younger women (Kandel et al. 1997; Substance Abuse and Mental 
Health Services Administration 2012). The prevalence of nicotine and alcohol 
dependence together in an individual suggests that the occurrence of one may not be 
independent of the other (Anthony and Echeagaray-Wagner 2000; Grucza and Bierut 
2006b; Kahler et al. 2008).  
 
Drug exposure during pregnancy has long been suspected to exert deleterious effects on 
the fetal brain.  Compared with other likely drugs of abuse, smoking during pregnancy is 
less likely to decline throughout and continue after birth, thus exposing the child to 
second hand smoke (Cornelius and Day 2000).  Maternal smoking has been correlated 
with low birth weight, behavioral problems, and initiation of smoking (Ernst et al. 2001; 
Kandel et al. 2007).  In addition, the occurrence of sudden infant death has been 
correlated with maternal smoking (Lavezzi et al. 2013).   Adolescent male children of 
mothers that smoke demonstrated a four-fold increase in the incidence of conduct 
disorder compared to male children of nonsmokers (Ernst et al. 2001).  The female 
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adolescent children had a five-fold increase in frequency of drug abuse compared to 
children of nonsmokers (Ernst et al. 2001).  It has also been shown that respiratory 
illnesses such as asthma are more common in children born to mothers who smoke 
(Maritz and Mutemwa 2012).   
 
Evidence suggests that alcohol exposure during pregnancy at any stage in development 
can cause harm to the child (Kuczkowski 2007).  The harmful properties of alcohol are 
well known because of its ability to easily cross the placental barrier (Kuczkowski 2007).    
Children exposed to larger amounts of alcohol prenatally can have changes in brain 
function as well as brain structure (Mattson et al. 2001). There is no safe level of alcohol 
intake during pregnancy, moreover, since alcohol can be transmitted through breast milk 
it is recommended that mothers refrain from drinking after giving birth (Substance Abuse 
and Mental Health Services Administration).  Consequences of alcohol exposure during 
pregnancy are characterized as fetal alcohol syndrome and fetal alcohol spectrum 
disorder, which includes behavioral problems and poor social skills (Greenbaum et al. 
2009). 
 
An investigation into the occurrence of smoking during pregnancy by teenage mothers 
found that 58 percent of those who smoked reported concurrent use of alcohol during 
pregnancy (Cornelius et al. 2007).  Given the frequency of concurrent nicotine and 
alcohol use, the disorders seen in children with gestational drug exposure may be 
partially due to the effects of both drugs (Buka et al. 2003; Cornelius and Day 2000; 
Greenbaum et al. 2009; Kandel et al. 2007).  The low birth weight seen in children with 
prenatal nicotine exposure often normalizes over time, however not when combined with 
prenatal alcohol exposure (Ernst et al. 2001).  Both nicotine and alcohol attack the 
developing brain. Despite the frequency of concurrent use of both drugs, the gestational 
exposure to these drugs is typically studied separately, rather than together.  
 
Our lab has developed a 3-trimester gestational model to study the combined effects of 
nicotine and ethanol exposure (Matta and Elberger 2007).  Epidemiologically, women 
who do not stop smoking and/or drinking upon learning they are pregnant (first 
trimester), usually continue drug use throughout the entire pregnancy (Substance Abuse 
and Mental Health Services Administration),  thereby exposing the fetal brain throughout 
the entire three trimesters.  Most animal models of human drug use during pregnancy 
expose only the pregnant dam to the drug, and therefore, once the pups are born they no 
longer receive drug exposure.  However, the first 12-14 postnatal days in a rodent are 
critical because they are the rodent developmental equivalent of the human third trimester 
(Dwyer et al. 2009).  This is a period of rapid brain growth and synaptogenesis.  
Therefore, full gestational drug exposure, equivalent to the entire 3-human trimesters, 
requires postnatal drug treatment as well.  We have previously shown the enhanced 
acquisition of nicotine self-administration in nicotine and ethanol (Nic+EtOH) offspring 
as adults (Matta and Elberger 2007) demonstrating that neuroplasticity induced by 
gestational drug exposure is a long lasting brain alteration.  However, the mechanisms 
underlying this alteration are unknown. 
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The mesocorticolimbic pathway, which is essential for motivated drug-taking behavior, is 
comprised of the midbrain ventral tegmental area (meso; VTA), the forebrain nucleus 
accumbens (limbic; NAcc), and the medial prefrontal cortex (cortico; mPFC) (Koob and 
Nestler 1997). We are focused on the critical VTA dopaminergic (DA) neurons 
projecting to NAcc and their regulation, in part, by inhibitory λ-aminobutyric acid 
(GABA) (Figure 1.1) (Laviolette and van der Kooy 2004), as well as excitatory 
glutamatergic inputs (Mansvelder et al. 2003).  The excitatory glutamatergic inputs arrive 
from cortex, laterodorsal tegmental nucleus (LDTg, and from local VTA glutamate 
neurons (Tolu et al. 2013).  The inhibitory transmitter GABA modulates the DA neurons 
by inputs from NAcc, ventral pallidum (VP), pedunculopontine tegmental nucleus 
(PPTg), and from local interneurons (Adell and Artigas 2004; Tolu et al. 2013).  
 
We have previously shown that i.v. nicotine resulted in an increase in accumbal DA 
release at doses as low as 60µg/kg in adult rats (Fu et al. 2000).  However, only higher 
doses of nicotine (90µg/kg and higher) were able to produce an increase of VTA 
glutamate release (Fu et al. 2000).  In addition, we have shown that the increase in NAcc 
DA and VTA glutamate in response to nicotine can be disrupted with intra-VTA infusion 
of an NMDA receptor antagonist (Fu et al. 2000).  Disruption of reward-related learning 
can also be disrupted with the use of a NMDA receptor antagonist (Zellner et al. 2009).  
Additional studies have examined the modulation by inhibitory GABA on VTA DA 
neurons. The infusion of intra-VTA baclofen (GABA B receptor agonist) was able to 
reduce extracellular accumbal DA (Westerink et al. 1996).  In addition it has been shown 
that the intra-VTA baclofen is able to disrupt nicotine SA behavior (Paterson et al. 2004). 
 
The mesocorticolimbic pathway, specifically in the VTA, has been implicated in the use 
of EtOH. Studies using anesthetized rats demonstrated that low dose ethanol (0.01-0.03 
g/kg) increases VTA GABA firing (Steffensen et al. 2009), whereas higher doses of 
ethanol  (0.2-2.0 g/kg) demonstrate an inhibition of GABAergic activity (Gallegos et al. 
1999).  An electrophysiological study examined modulation of VTA DA neurons after 
chronic exposure to ethanol in C57BL/6J mice.  VTA DA neurons following chronic 
ethanol displayed less inhibition by GABA compared to saline controls (Brodie 2002).  
However, the neurons with chronic ethanol displayed no difference in the presence of 
NMDA when compared to those with saline exposure (Brodie 2002).  Voluntary intake of 
ethanol by C57BL/6J mice using a model called “drinking in the dark” showed that the 
mice would drink until intoxicated.  This model of ethanol intake can be disrupted by 
mecamylamine (nACh antagonist) (Hendrickson et al. 2009). 
 
In addition, a study has shown that low doses of Nic+EtOH administered systemically 
produce an additive effect on NAcc shell DA release (Tizabi et al. 2007).  This release 
can be blocked using systemic mecamylamine (Tizabi et al. 2007).  This study provides 
some evidence for the prevalence of concurrent use of nicotine and alcohol. 
 
In summary, nicotine and ethanol each exert profound effects on brain development, 
resulting in long-lasting behavioral alterations.  The clinical outcomes of such 
developmental aberrations in mesocorticolimbic mechanisms that underlie addictive 
behavior are just now being investigated.  Yet, the consequences of exposure to both  
4  
 
 
Figure 1.1:  Schematic representation of the VTA and afferents.  The DA (Green) 
output neuron is regulated by glutamate (Purple) and GABA (Blue) neurotransmitters in 
the VTA (grey shaded area).  DA neurons are modulated by glutamate projections from 
cortex, LDTg, PPTg and from local interneurons.  GABA local interneuons inhibit DA 
neurons as well as projections from NAcc and VP. 
 
Source: Adapted by permission from Macmillan Publishers Ltd: Tolu S, Eddine R, Marti 
F, David V, Graupner M, Pons S, Baudonnat M, Husson M, Besson M, Reperant C, 
Zemdegs J, Pages C, Hay YA, Lambolez B, Caboche J, Gutkin B, Gardier AM, 
Changeux JP, Faure P, Maskos U (2013) Co-activation of VTA DA and GABA neurons 
mediates nicotine reinforcement. Mol Psychiatry 18: 382-93. 
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agents has not been studied experimentally, despite strong epidemiological evident for 
co-morbid effects due to the high prevalence of cigarette smoking by young women who 
consume alcohol during their child-bearing years.   
 
For these reasons, we used our model of gestational Nic+EtOH exposure to examine the 
long-term alterations in the offspring. We hypothesize, that the gestational drug exposure 
to the combination of nicotine and ethanol results in a long-term alteration in 
glutamatergic and GABAergic function in the VTA of adult and adolescent Nic+EtOH 
offspring, which contributes to their enhanced acquisition of nicotine self-administration 
behavior.  The objectives of the studies were to: (A) Determine whether the enhanced 
nicotine SA of Nic+EtOH offspring is the result of maternal-offspring interactions or the 
gestational drug treatment.  (B) Investigate the role of the mesocorticolimbic pathway in 
nicotine SA, specifically changes in glutamate and GABA modulation of VTA DA 
neurons of Nic+EtOH offspring compared to PF controls.
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CHAPTER 2.    FOSTERING ITSELF INCREASES NICOTINE SELF-
ADMINISTRATION IN YOUNG ADULT MALE RATS* 
 
 
Introduction 
 
Drug exposure during pregnancy has long been reported to negatively affect the 
development of the fetal brain (Stanwood and Levitt 2004).  Maternal behavior in the 
postnatal environment is also known to play an important role in determining offspring 
behavior in adolescence and adulthood (Barbazanges et al. 1996). Fostering offspring to 
drug naïve dams has long been considered necessary to control for lingering drug effects 
on the dam that may further alter offspring growth and development (Abel and Dintcheff 
1978; Golub and Kornetsky 1975). It has become almost dogma in the literature that 
maternal prenatal drug exposure is a negative contributor to subsequent maternal-
offspring interaction.  This has resulted in the implementation of fostering as a standard 
practice without actual empirical testing of the effect that fostering itself may exert.  
 
Our laboratory has previously shown that young adult male rats exposed to nicotine and 
ethanol (Nic+EtOH) throughout full gestation [i.e., gestational days (GD) GD2-20 and 
during postnatal days 2-12 (PN2-12), the rodent third trimester-equivalent of human 
gestation during which rapid brain growth and synaptogenesis occur (Dwyer et al. 2009; 
Puglia and Valenzuela 2010), exhibit increased acquisition of nicotine self-administration 
(SA) behavior (Matta and Elberger 2007).  In addition, there were no significant 
differences in standard birth parameters between Nic+EtOH offspring and controls 
(Matta and Elberger 2007). Regardless, a frequent concern of grant and manuscript 
reviewers is adherence to the literature standard insists on fostering/cross-fostering all 
offspring to surrogate dams.  With careful examination of the historical literature on 
gestational drug treatment protocols, it appears that the requirement of fostering has been 
based, at least in part, on studies of fetal alcohol syndrome (FAS).  In such studies, the 
pregnant/nursing dam received gavaged EtOH at doses that raised her blood ethanol 
concentration (BEC) to approximately 340mg/dl or greater (Abel and Dintcheff 1978), 
doses rarely seen in the human population.  In these reports, the dams that did manage to 
survive the EtOH dosing showed significant intoxication, including staggering gait, 
slowed respiration, and in many cases comatose behavior that lasted for > 2h.  Offspring 
that survived this dosing protocol were born late, had low birth weights, and showed 
delayed maturation parameters (Eppolito and Smith 2006). Obviously, maternal-offspring 
interactions were compromised.  In contrast, our dosing protocol produced BECs’ of 
approximately 150mg/dl and the dams showed no differences in retrieval or covering 
behavior (data not shown).  The aim of the current study was to determine whether 
fostering would modify the increased acquisition of nicotine SA behavior, previously 
seen in offspring with full gestational (GD2-PN12) exposure to Nic+EtOH compared to 
pair-fed (PF) controls. 
________________________________________________________________________ 
*Reprinted with permission from Springer and Psychopharmacology. Roguski EE, 
Chen H, Sharp BM, Matta SG. Fostering itself increases nicotine self-administration in 
young adult male rats. Psychopharmacology 2013 Sept;229(2)227-34. 
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Based on the complete lack of differences in litter parameters reported by Matta and 
Elberger (2007), we felt it was critical to determine if the increased SA behavior of the 
Nic+EtOH offspring compared to PF controls was the due to the effect of the drugs on 
the developing pups or the indirect effect of changes in maternal-offspring interaction.   
We found that fostering itself has a significant effect on locomotor activity regardless of 
gestational treatment.  Surprisingly, fostering increased nicotine SA only in the fostered 
PF controls, so that the behavior resembled that seen in the drug treated Nic+EtOH 
offspring.  Therefore, our results show that fostering itself can contribute to altered 
behavior in the offspring, demonstrating that fostering is not an neutral control.  Rather, it 
should be considered a unique experimental condition that specifically interacts with 
other treatments. 
 
 
Materials and Methods 
 
 
Breeding and Gestational Drug Exposure:  The model of gestational exposure was 
conducted as described in Matta and Elberger (2007).  Briefly, Sprague-Dawley rats 
(Harlan, IN, USA) were group housed with a reverse light cycle (11 AM off and 11 PM 
on).  Female rats were paired with male breeders overnight and then randomly assigned 
to the experimental Nic+EtOH group, or the controls (Nicotine-alone or PF groups) on 
sperm positive day 1 (GD1).  Pair feeding was accomplished by providing the control 
dams with the same amount of food consumed by the Nic+EtOH dam on the same 
gestational day.  For prenatal drug exposure of the experimental Nic+EtOH group, EtOH 
was administered by daily gastric gavage of 4g/kg from GD2 until GD20 and nicotine 
2mg/kg/day (pH = 7.2; calculated as free base; (−)-Nicotine hydrogen tartrate salt; Sigma 
Aldrich Co., St. Louis, MO, USA) was delivered by mini-osmopump (Alzet 2ML4; 
Durect, Cuppertino, CA, USA) implanted on GD3 (Figure 2.1A).  For prenatal exposure 
in PF dams, isocaloric maltose dextran (MD) was gavaged, instead of EtOH, and dams 
received a water-filled mini-osmopump (Figure 2.1B).  Prenatal Nicotine-alone dams 
were gavaged with MD and fitted with a 2mg/kg/day nicotine mini-osmopump, to serve 
as the surrogate for Nic+EtOH offspring (Figure 2.2A).  After birth (PN0), litters were 
randomly culled to 10 pups (5 female + 5 male when possible) on PN1 and drug 
treatments continued from postnatal PN 2-12, the rodent equivalent of the human third 
trimester.  For both fostered and non-fostered Nic+EtOH offspring, the nicotine mini-
osmopump in their dam (Nic+EtOH and Nicotine-alone) was replaced on PN2 with one 
containing 8mg/kg/day, in order to deliver sufficient nicotine to the pups through the 
dams’ milk, as reported previously (Matta and Elberger 2007); EtOH was delivered by 
gavaging the offspring twice daily, 30 minutes apart, for a total of 4g/kg (Figure 2.1A).  
The non-fostered PF pups received 2 isocaloric MD gavages daily and nursed from their 
own dam, fitted with a new water mini-osmopump replaced on PN2 to control for 
surgical effects (Figure 2.1B).  All offspring were weaned at PN21, group housed by 
litter, and allowed to mature with unrestricted access to food and water until they were 
single housed starting on PN60 for nicotine SA experiments. Daily handling and pseudo-
gavaging of dams prior to pregnancy minimized stress.  Pups were never separated from 
their littermates, except when an individual pup was being gavaged (<1.5 min); each litter 
8 
 
Figure 2.1:  Protocol for drug treatments in non-fostered offspring.  (A) Dams 
designated as Nic+EtOH on GD1, received EtOH gavages (4g/kg) beginning on GD2 and 
a nicotine mini-osmopump (2mg/kg/day) implantation on GD3.  The non-fostered pups 
remained with their dam postnatally. Postnatal exposure to EtOH began on PN2 with 
twice daily gavages of EtOH (4g/kg total) to each pup.  Nicotine exposure was 
administered by replacing the nicotine pump (8g/kg) in the dam, so that the pups received 
nicotine through the dams’ milk. (B) PF dams received daily gavages beginning GD2 of 
MD (4g/kg) and a control mini-osmopump of water on GD2. These non-fostered pups 
also remained with their dam postnatally. Postnatal pup exposure with twice daily 
gavages of MD (4g/kg total) began on PN2 and a replacement control mini-osmopump 
was inserted in their dam on PN2. 
 
A. 
 
 
 
 
 
B. 
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Figure 2.2:  Protocol for drug treatments in fostered offspring. (A) Dams designated 
as Nic+EtOH received EtOH gavages (4g/kg) beginning on GD2 and a nicotine mini-
osmopump (2mg/kg/day) implantation on GD3.  Offspring were fostered on PN1-2 to a 
surrogate dam that received prenatal nicotine exposure (Nicotine-alone group) and whose 
pups were terminated at fostering.  Postnatal exposure to EtOH began on PN2 with twice 
daily gavages of EtOH (4g/kg total) to each offspring.  Nicotine exposure was 
administered by replacing the nicotine pump (8g/kg) in the surrogate dam, so that the 
pups received nicotine through the dams’ milk.  (B) PF offspring were fostered to 
different PF dams on PN1-2.  Postnatal exposure for the offspring was given by twice 
daily gavages of MD (4g/kg total) beginning on PN2 and a replacement control mini-
osmopump on PN2 in the surrogate. 
 
A. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B. 
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was returned to its dam within 5-6 minutes at which time every dam recollected and 
covered her litter regardless of treatment group.  All procedures were conducted in 
accordance with the NIH Guidelines for the Use and Care of Laboratory Animals and 
were approved by the Institutional Animal Care and Use Committee of the University of 
Tennessee Health Science Center.  
 
 
Fostering:  The fostering of the offspring was completed between PN1-2.  Surrogate 
dams were timed to deliver at the same time as Nic+EtOH or PF litters.  Since the 
experimental paradigm requires a 3-trimester equivalent drug exposure, postnatal 
Nic+EtOH offspring could not be fostered to a drug-naïve dam because the drug-naïve 
dam would have adverse reactions to the sudden exposure to an 8mg/kg/day nicotine 
mini-osmopump on PN2, which is required to deliver the appropriate dose of nicotine to 
the pups via the dams breast milk (Matta and Elberger 2007).  Therefore, the fostered 
Nic+EtOH pups were placed with the Nicotine-alone surrogate dam that had been 
exposed to 2mg/kg nicotine prenatally (GD1-21) and gavaged daily with MD; these 
Nic+EtOH pups were gavaged with EtOH daily (Figure 2.2A).  All the offspring from 
these designated Nicotine-alone surrogates were sacrificed at the time that the 
experimental Nic+EtOH offspring were fostered to those dams.  Fostered PF offspring 
were placed with a new PF dam that received a new water mini-osmopump on PN2 and 
the pups received MD from P2-P12 (Figure 2.2B). 
 
 
Litter Parameters:  In addition to those previously reported (Matta and Elberger 2007), 
additional litter parameters were measured on PN1 to determine if there were 
developmental alterations due to gestational drug treatment.  Pups with in utero exposure 
to Nic+EtOH or PF (n=9 each) from 5 Nic+EtOH litters and 4 PF litters were used to 
measure body weight (Bwt), volume distribution, crown-rump length, and brain weight.  
After Bwt measurement, the volume of water displaced when the pup was placed in a 
cylinder of water was determined, followed by measuring the length from the crown of 
the head to the beginning of the tail, and then the brain was removed and weighed.  Since 
there were no sex differences in these (or the previous) parameters, the data were pooled.  
 
 
Locomotor Activity:  Activity in a novel environment was measured for adolescent male 
offspring (PN45) with a Micromax monitoring system (Accuscan Instruments, 
Columbus, OH, USA).  Rats were placed in individual chambers (45×24×19cm) with 
dividers preventing each rat from observing the others.  Data were collected in 5-minute 
increments during 1 hour with the lights off. 
 
 
Nicotine Self-Administration:  Young adult male offspring (PN60-75) were allowed 
chronic, almost unlimited (i.e., 23 h/d) access to bar press for nicotine without prior 
training, shaping, or food deprivation, using our established model (Valentine et al. 
1997).  Briefly, after implantation of a jugular cannula, rats were placed into individual 
operant chambers (Coulbourn Instruments, Allentown, PA, USA) enclosed in ventilated, 
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sound-attenuating environmental boxes.  The jugular line was connected to a 
microinjection pump (Med Associates, St. Albans, VT, USA) by a single channel swivel 
(Instech, Plymouth Metting, PA, USA). Rats were given 3 d to recover from surgery; 
thereafter, rats were provided free access for 23 h daily (1 h daily is required for animal 
husbandry and downloading data) to two randomly assigned levers positioned 5 cm 
above the floor, each with a green light above signaling the availability of the drug. 
Pressing the active lever (“active”) signaled the computer (Graphic State Notation 
software, Coulbourn Instr.) to activate a pump that delivered 30µg/kg nicotine in a 50-µl 
heparinized saline bolus over 0.81 s on a fixed ratio (FR1) schedule with a 7 second 
delay; pressing the inactive lever (“inactive”) had no programmed consequence. Self-
administration day 1 (SA d1) was the first day nicotine was made available and the 
offspring were given 10 days free access to acquire nicotine SA on an FR1 schedule. 
 
As per our previously reported criteria for this open access model (Valentine et al. 1997), 
acquisition of nicotine self-administration behavior to maintenance criteria was defined 
by: (1) stabilization of the number of active bar presses on the final 3 d to within 15% 
variation, (2) active bar presses greater than inactive presses, and (3) active presses 
greater than 12/day.  
 
 
Statistics: Three-way ANOVA analyses were completed for SA, locomotor activity and 
the offspring growth curve to examine the interaction between cohort and fostering.  One-
way ANOVA analysis was completed for litter parameters with a Scheffe post-hoc 
comparison using SPSS software; significance was set at p<0.05. To reduce the number 
of animals used, once statistical significance was achieved, further rats were not tested.  
Values are mean + SEM and the number of animals/group is indicated within parentheses 
in the text and figures. 
 
 
Results 
 
 
Litter Parameters:  Litter parameters were measured on PN1 using 2 pups per treatment 
group for Nic+EtOH (n=9) and PF cohorts (n=9) (Table 2.1).   These parameters were 
chosen because they are indicators of exposure to doses of gestational EtOH, used in 
models of FAS; such doses are greater than that administered in the current study. In 
marked contrast to reports on FAS, there were no differences in volume distribution, 
crown-rump length, or brain weight for Nic+EtOH or their PF controls. Similar to 
previous observations (Matta and Elberger 2007), there was no significant difference in 
the birth weight between the Nic+EtOH and PF offspring. In addition, peak BECs in 
Nic+EtOH dams and their offspring (154+6 and 151+6 mg/dl, respectively) were 
comparable to those commonly reported in humans cited for a DWI (i.e., driving while 
intoxicated) violation (Matta and Elberger 2007).  Also, peak plasma nicotine levels 
(30+3 and 21+2 ng/ml, respectively)  were lower than those eliciting nicotine-induced 
hypoxia (Slotkin et al. 1987). These data demonstrate that offspring were exposed to 
moderate doses of EtOH similar to those frequently imbibed by human binge drinkers
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Table 2.1:  Litter parameters. 
 
Cohort Birth Weight 
PN1 (g) 
Volume 
Displacement (ml) 
Crown-Rump  
Length (cm) 
Brain  
Weight (mg) 
Nic+EtOH 
(n=9) 
6.2 ± 0.3 5.8 ± 0.4 4.2 ± 0.1 255.3 ± 6.9 
PF 
(n=9) 
6.5 ± 0.2 5.9 ± 0.2 4.3 ± 0.1 246.3 ± 8.4 
 
No significant differences were seen for birth weight (PN1), volume distribution, crown-
rump length, and brain weight.  This demonstrates that the gestational drug exposure did 
not have any overt developmental effect on the offspring (Results are reported as average 
+ SEM). 
 
 
and moderate smokers. Taken together, these data indicate that gestational drug treatment 
did not alter general indices of offspring health. 
 
 
Offspring Growth Curve:  Figure 2.3 illustrates postnatal body weight gain among 
treatment groups. Fostering had no effect on body weight gain in the Nic+EtOH 
offspring, nor did it alter weight gain in the PF offspring; weight gain was similar in both 
treatment groups (p=0.27).  These data demonstrate that neither fostering nor drug 
treatments altered growth during postnatal drug administration. 
 
 
Locomotor Activity:  Fostered Nic+EtOH and PF offspring had a higher total activity 
over the 1 hour session on PN45 compared to non-fostered Nic+EtOH and PF offspring 
(F1,348=4.1; p<0.05) (Figure 2.4).  Similarly, the non-fostered offspring (Nic+EtOH and 
PF) did not differ significantly from each other nor did the fostered Nic+EtOH and PF 
offspring behaviors differ.   
 
 
Nicotine Self-Administration:  To demonstrate that offspring learned the SA behavior 
active vs. inactive lever presses were compared. Both non-fostered and fostered PF rats 
expressed significant higher active lever presses compared to inactive lever presses for 
the entire 10-day period of nicotine SA behavior; PF non-fostered offspring (F1,100=97.36 
p<0.01); PF fostered (F1,100=150.68, p<0.01). Surprisingly, the fostered PF offspring had 
significantly increased nicotine SA compared to non-fostered PF offspring (F1,100=16.55, 
p<0.01) (Figure 2.5A). Furthermore, fostered offspring acquired the behavior by d4 
(p<0.05, active vs. inactive bar presses by day), while non-fostered required a longer time 
interval (d8; p<0.05, active vs. inactive presses by day).  Fostered PF offspring also 
exhibited significantly more bar presses than the non-fostered group during the last 3 d: 
77±8 vs. 50±8 fostered vs. non-fostered, respectively (F1,34=5.7, p=0.02).   
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Figure 2.3:  Postnatal Bwt gain in fostered and non-fostered Nic+EtOH and PF 
offspring.  Bwt gain was not influenced by full gestational exposure nor by postnatal 
fostering.  
 
 
 
 
 
Figure 2.4:  Locomotor activity for fostered and non-fostered Nic+EtOH and PF 
offspring at PN45.  Fostered offspring demonstrated a higher number of beam breaks 
compared to the non-fostered offspring, regardless of full gestational drug treatment.  
This demonstrates that fostering itself can increase activity in a novel environment 
(Fostered vs. Non-fostered offspring *p=<.05). 
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Figure 2.5: Nicotine SA of fostered and non-fostered PF and Nic+EtOH offspring. 
(A) In the PF control young-adult offspring, fostering alone significantly increased 
nicotine SA. PF offspring, both fostered and non-fostered, were given 23-hour access to 
acquire self-administration of 30ug/kg/inj of nicotine without priming, shaping, or 
training.  Fostering increased lever presses on the active bar delivering nicotine 
30µg/kg/inj (solid line), without affecting behavior on the inactive bar (no consequences 
lever; dashed line); *p<0.05, Active bar presses, PF non-fostered vs. PF fostered.  (B) 
Fostering had no effect on the nicotine SA by the Nic+EtOH young adult offspring.  Full 
gestational exposure (GD2-PN12) to Nic+EtOH resulted in increased levels of nicotine 
SA, as well as a shortening in the onset of initiation of nicotine SA, regardless of 
fostering status.  Surprisingly, PF controls that had been fostered, but had no gestational 
drug exposure, demonstrated comparable levels of nicotine SA to Nic+EtOH offspring.  
 
 
A. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B. 
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In contrast, Figure 2.5B shows that fostering Nic+EtOH offspring did not alter their SA 
behavior (p=0.99 for Nic+EtOH vs. Nic+EtOH Fostered). Active bar presses were greater 
than inactive presses in both groups: non-fostered Nic+EtOH offspring (F1,120=136.91 
p<0.01); Nic+EtOH Fostered (F1,120=70.67 p<0.01; data not shown).  Non-fostered 
Nic+EtOH, fostered Nic+EtOH, and fostered PF offspring showed significantly higher 
levels of nicotine SA in comparison to non-fostered PF offspring (active bar presses:  
F1,220=6.62, p<0.01).  
 
 
Discussion 
 
Our data show that early postnatal fostering per se markedly increased nicotine SA in 
young adult PF offspring – the control group for Nic+EtOH full gestational treatment.  
These results indicate that the alteration of postnatal environment (i.e. maternal behavior; 
maternal grooming, nursing, etc.) increases the long-term drug taking behavior of the 
offspring.  
 
There is a limitation of the three-trimester model of full gestational drug exposure, which 
was designed to approximate full three-trimester exposure in humans.  During the third 
trimester (i.e. postnatally) in this model, we have attempted to approximate the 
continuous exposure of the postnatal pups to the blood nicotine levels they had while in 
utero.  In contrast, since the EtOH was administered to the pregnant dams as a binge 
dose, we also administered the EtOH to the postnatal pups as a binge dose in order to 
control for BEC.  That is, even if we had gavaged the nursing dam, there was no way we 
could guarantee that each individual pup would drink sufficient breast milk with EtOH 
within the timeframe of EtOH metabolism in the dam. 
 
Full gestational exposure to relatively moderate amounts of both nicotine and EtOH did 
not alter birth parameters (PN1) or body weight gain in offspring (PN1-PN21) compared 
to PF controls.  These results are in agreement with our previous report in which sex 
ratio, stillbirths, righting reflex, and the day of eye opening were similar between all 
treatment groups (Matta and Elberger 2007). Previous studies have shown that gestational 
EtOH exposure (4g/kg and 6g/kg) was associated with low birth weight and behavioral 
abnormalities in the offspring (Abel 1978; Abel and Dintcheff 1978).  However, the 
outcome of low birth weight was inconsistent, even following relatively high doses of 
6g/kg (Caul et al. 1979; Matta and Elberger 2007; Osborne et al. 1980); this could reflect 
differences in the mode of EtOH delivery or rat strain. Prenatal nicotine exposure has 
also been associated with low birth weight of pups, however this is seen only at higher 
doses (>6mg/kg/day) and not at the lower dose used herein (i.e., 2mg/kg/day) (Eppolito 
and Smith 2006; Navarro et al. 1989; Slotkin et al. 1987).  Depending on drug and dose, 
prenatal drug exposure also may modify aspects of the postnatal environment.  It has 
been shown that offspring with prenatal EtOH exposure fail to gain weight at the same 
rate as control offspring after being born with low birth weight and this lack of weight 
gain was thought to be attributed to factors in the postnatal environment (i.e. the drug 
exposed dam) and not to the prenatal EtOH exposure itself (Abel and Dintcheff 1978).  In 
contrast, cross-fostering of control offspring to EtOH exposed dams did not alter the 
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weight gain of these offspring, demonstrating that the EtOH-treated dams themselves did 
not adversely affect the growth of the offspring (Osborne et al. 1980).  Despite the lack of 
any correlation between drug-exposure in dams and offspring behavior, the authors of 
that early report still strongly recommended fostering to drug naïve-dams. However, our 
results show that regardless of gestational treatment (Nic+EtOH or PF), the postnatal 
growth curves for non-fostered offspring were consistent with our previous report (Matta 
and Elberger 2007) and did not differ from each other.  Taken together, these data 
indicate that neither fostering nor gestational drug treatment altered the overall bodily 
growth and gross CNS maturation of offspring. 
 
Fostering at different postnatal time points can exert divergent effects on behavior 
(Barbazanges et al. 1996; Darnaudery et al. 2004). It has been reported that maternal 
separation stress in early human life dysregulates the hypothalamic-pituitary-adrenal 
(HPA) stress axis, thus increasing the risk for drug taking behavior (Andersen and 
Teicher 2009; Vallee et al. 1999). Also, rat offspring fostered at PN5 or PN12 displayed 
enhanced stress responses, similar to those detected in offspring exposed to maternal 
separation at the same time intervals (Barbazanges et al. 1996).  However, offspring 
fostered at PN1 did not display these increased stress responses (Darnaudery et al. 2004). 
In rodents, prolonged maternal separation stress (3h) at different postnatal ages increased 
subsequent dopamine responses to stress or stimulants in the mesocorticolimbic reward 
pathway (Brake et al. 2004).  This reward pathway, which includes the ventral tegmental 
area, nucleus accumbens, and medial prefrontal cortex, is essential to the acquisition of 
drug self-administration (Koob and Nestler 1997).  In addition to reported alterations in 
the HPA axis, altered maternal-offspring interactions also can affect components of this 
reward pathway. For example, repeated or acute separation stress (1-3h/daily from PN3-
21), altered multiple neuronal circuits.  Specifically, 1-hour separation from PN1-20 
increased serotonin levels and serotonin turnover (5-HIAA/5HT ratio) in medial 
prefrontal cortex and hippocampus (Jezierski et al. 2006), while 1-hour separation from 
PN1-21 increased GABA in the medial prefrontal cortex (Helmeke et al. 2008).  Finally, 
a recent report (Champagne and Curley 2009) showed that cross-fostering of drug naïve 
WKY pups to an spontaneous hypertensive rats (SHR) surrogate rat caused a shift in 
phenotype to that of SHR.  Studies in progress are centered on modulation of GABAergic 
inhibition and glutamatergic excitation in the VTA of the Nic+EtOH offspring, as well as 
specific epigenetic changes, such as DNA methylation in these neuronal types. 
 
The fostering/cross-fostering of offspring and the resultant locomotor activity has been 
reported to produce varied results. While offspring fostered on PN1 did not differ from 
controls, groups with maternal separation from the dam had higher locomotor response 
(Barbazanges et al. 1996).  Adult rats fostered at later neonatal time points (PN5 or 
PN12) had a significantly higher locomotor responses compared to non-fostered offspring 
(Barbazanges et al. 1996).  Also, it has been reported that neither fostering nor cross-
fostering of Wistar and Fisher rats altered total motor activity for open field behavior.  In 
contrast, a report on the cross-fostering of Lewis and Fisher strains demonstrated 
significant differences in locomotor activity for both males and females, whereas in-strain 
fostering of the offspring produced no differences in activity (Gomez-Serrano et al. 
2001).  Locomotor activity to a novel environment has been used in the past to separate 
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animals into higher anxiety vs. lower anxiety responder groups (Gancarz et al. 2011).    
High responder groups of younger rats (4 months old) have been associated with 
increased HPA axis activity in response to stress (Dellu et al. 1996).  Responding for 
nicotine, methamphetamine, and even visual stimulus, has also been correlated with high 
locomotor response to novelty (Gancarz et al. 2011; Suto et al. 2001).  Our locomotor 
results show that only fostered offspring, regardless of full gestational treatment group, 
had an increased response to a novel environment in adolescence. In addition, the 
inactive lever presses during self-administration did not increase with prenatal drug 
exposure or fostering, therefore demonstrating that offspring were not hyperactive in the 
SA chambers.  We conclude from this that increased locomotor activity in a novel 
environment is not necessarily a predictor of a high nicotine self-administration. 
 
In our study, we did not expect to see behavioral changes, since the PF control offspring 
were fostered on PN1 and there were no differences in litter parameters.  Yet, we found 
dramatic increases in the nicotine SA behavior of fostered PF offspring that was 
comparable to the behavior of experimental offspring with full gestational exposure to 
Nic+EtOH.  Self-administration behavior of the non-fostered PF offspring remained 
consistent with data previously reported (Matta and Elberger 2007).  Active bar presses 
were less in non-fostered than fostered PF (e.g. 50+8 vs. 77+8) and acquisition time was 
longer (i.e. 8 days compared to 4 days for Nic+EtOH).  Therefore, fostering alone, even 
in the absence of gestational exposure to drugs, is sufficient to alter nicotine SA behavior.  
In contrast, fostering itself did not change the enhanced nicotine SA behavior of 
Nic+EtOH pups.  There were no differences in the number of active bar presses, in the 
ratio of active to inactive presses or in the number of days to acquire stable nicotine SA. 
The lack of any effect of fostering in these pups could be due, at least in part, to a 
maximal or “ceiling” effect of gestational drug treatment on the developing brain of 
Nic+EtOH offspring.  
 
Variability in the effect of fostering has been reported for various drugs.  Rats with 
prenatal methamphetamine exposure (5mg/kg/day) show improvement in maturation tests 
when fostered to drug-naïve dams (Pometlova et al. 2009).  Similarly, while non-fostered 
rat offspring with in utero saline or morphine exposure (5mg/kg injection GD11-13, 
10mg/kg GD14-18) did not exhibit higher operant response rates for cocaine 
(0.5mg/kg/inj) compared to controls, fostering itself increased responding for cocaine 
regardless of prenatal treatment group (Vathy et al. 2007). In our previous study, cross-
fostering of offspring with prenatal nicotine exposure (3mg/kg/day) did not affect the 
increase in the dopaminergic response to a nicotine injection.  However, cross-fostering 
of controls resulted in an increase in accumbal dopamine similar to that seen in offspring 
with prenatal nicotine exposure (Kane et al. 2004).  These studies, as well as our data 
herein, support the idea that the fostering procedure itself, assumed to reduce negative 
maternal effects by many, is contraindicated and may actually introduce new sources of 
variance, subsequently changing pup behavior (Darnaudery et al. 2004).   
 
In summary, fostering of PF offspring significantly increased the nicotine SA behavior in 
young adult rats without altering the enhanced SA behavior of the Nic+EtOH offspring. 
Indeed, the experimental practice of fostering alone elevated the nicotine self-
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administration behavior of PF offspring to levels comparable to these Nic+EtOH rats. 
Therefore, in the current model of unlimited (i.e. 23-hour) nicotine access, fostering 
introduces a major confound that precludes its use as a control for environmental 
interactions during the neonatal period for our full gestational model of Nic+EtOH 
exposure.  Thus, the dogmatic assertion that fostering is a crucial control is inaccurate, 
rather fostering is its own experimental variable.  
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CHAPTER 3.    GESTATIONAL AND NEONATAL EXPOSURE TO NICOTINE 
AND ETHANOL RESULTS IN LONG-TERM GABA DYSREGULATION IN 
THE VENTRAL TEGMENTAL AREA 
 
 
Introduction 
 
Drug exposure during pregnancy has long been known to exert deleterious effects on the 
fetal brain. For example, maternal smoking has been correlated with low birth weight, 
behavioral problems, and nicotine dependence (Buka et al. 2003; Cornelius and Day 
2000). Alcohol exposure during pregnancy is characterized by fetal alcohol syndrome 
and fetal alcohol spectrum disorder, which also include behavioral problems and poor 
social skills (Buka et al. 2003; Cornelius and Day 2000; Greenbaum et al. 2009; Kandel 
et al. 2007).  Since women of child-bearing age frequently use nicotine and alcohol 
together (Substance Abuse and Mental Health Services Administration 2012), these 
disorders may be the result of the combined effects of both drugs.  Despite the high 
frequency of concurrent use of both drugs, most preclinical investigations on the 
neurological consequences of gestational drug exposure studied either nicotine or 
alcohol--missing the potential synergistic effects of these two drugs.  
  
Our lab has reported a model of 3-trimester gestational exposure to nicotine and ethanol 
(Nic+EtOH) (Matta and Elberger 2007). To expose the developing rodent brain to 
Nic+EtOH throughout 3 trimesters equivalent to human gestation, this model continues 
drug treatment during the first 12 postnatal days; this  is the rodent equivalent of the 
human third trimester, a period that is critical for brain development.  We have reported 
that full gestational exposure to Nic+EtOH  enhanced the acquisition of nicotine self-
administration (SA) behavior (i.e. faster acquisition and higher level of responding) .  
 
The mesocorticolimbic pathway central to drug-seeking behavior is comprised of the 
midbrain ventral tegmental area (VTA), the forebrain nucleus accumbens (NAcc), and 
the medial prefrontal cortex (mPFC) (Koob and Nestler 1997; Tolu et al. 2013). 
Dopaminergic (DA) neurons projecting from the VTA to NAcc are modulated, in part, by 
afferent inputs containing excitatory glutamate from cortex, laterodorsal tegmental 
nucleus, and local VTA neurons or inhibitory GABA modulators from ventral pallidum 
and local inhibitory GABA interneurons (Laviolette and van der Kooy 2004).  During 
development, GABA neurotransmission changes from excitatory to inhibitory, and 
nicotinic activity is responsible for this transition (Liu et al. 2006).  Modulation of 
cholinergic, glutamatergic, and GABAergic neurotransmission during development by 
nicotine and alcohol exposure could alter brain development, resulting in long lasting 
changes in brain circuitry that affect behavior such as the enhanced acquisition of 
nicotine SA (Tolu et al. 2013). 
 
In the VTA, both DA and GABA neurons express inhibitory GABA-B receptors, and 
intra-tegmental GABA exerts a tonic inhibitory effect on DA neurons (Kalivas 1993).  
Altered regulation by the GABA-B receptors expressed by GABA and DA neurons 
would affect this inhibition, particularly since DA neurons have few GABA-A receptors 
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(Kalivas 1993).  Since it has been shown that elevations in VTA GABA levels block 
nicotine SA (Corrigall et al. 2000), a decrease in GABA modulation of DA neurons 
would be expected to increase nicotine-stimulated DA release and enhance nicotine SA.  
Given the enhanced nicotine SA seen in offspring with Nic+EtOH exposure, we focused 
on clarifying the GABAergic regulation of dopamine projections from the VTA to NAcc 
shell.  We postulate that GABAergic dysregulation due to full gestational exposure to 
Nic+EtOH is one key mechanism contributing to the vulnerability to acquire nicotine SA 
in these offspring. 
 
 
Materials and Methods 
 
 
Animals and Gestational Exposure:  Sprague-Dawley rats (Harlan Laboratories) were 
group housed on a reverse light cycle (11AM off and 11PM on) for all experiments.  The 
model of gestational exposure was developed on site and described (Matta and Elberger 
2007).  Briefly, female rats were housed with male breeders overnight until sperm 
positive.  Then the females were single housed and placed into one of four groups; the 
Nic+EtOH, nicotine alone (Nic), ethanol alone (EtOH), or pair-fed (PF) group.  All dams 
were fed according to the amount of feed consumed by the Nic+EtOH dam they paired 
to.  The EtOH prenatal exposure (Figure 3.1A and 3.1C) was given by daily gavage of 
4g/kg from gestational day 2 (GD2) until GD20.  The model utilizes a low dose to mimic 
moderate drinking.  Nicotine was administered prenatally by implantation (Figure 3.1A 
and 3.1B) of a mini-osmopump (Alzet 2ML4; Durect, Cupertino, CA, USA) delivering a 
constant 2mg/kg dose (pH = 7.2; calculated as free base; (−)-Nicotine hydrogen tartrate 
salt; Sigma Aldrich Co., St. Louis, MO, USA).  The dose chosen approximates 1-2 packs 
of cigarettes per day.  For the Nic (Figure 3.1B) and PF (Figure 3.1D) groups, dams 
were gavaged with maltose dextran to equal the calories given to Nic+EtOH and EtOH 
groups.  After the pups were born they received Nic+EtOH treatments (Figure 3.1) from 
postnatal day 3 (PND3) until PND12, this was to mimic the third trimester of pregnancy.  
The nicotine mini-osmopump in the dam was replaced on PND 2 with an 8mg/kg dose.  
The nicotine is delivered to the pups through the breast milk.  Ethanol was given by two 
pup gavages of 2g/kg each, 30 minutes apart.  Pups not receiving ethanol gavages were 
instead given matched gavages of maltose dextran (MD).  The pups were weaned at 
PND21.  The offspring were given full access to food and water and used at PND60 for 
the proposed experiments.  All procedures were conducted in accordance with the NIH 
Guidelines for the Use and Care of Laboratory Animals and were approved by the 
Animal Care and Use Committee of the University of Tennessee Health Science Center.   
 
 
Brain Cannulae Implantation:  Animals were anesthetized with a cocktail containing 43 
mg/kg ketamine and 8.6 mg/kg xylazine before being placed in a David Kopf stereotaxic 
instrument.  Animals received two implantations of 20 gauge  (20 mm) guide cannulae.  
One was   placed in the posterior VTA (A.P, -5.6 mm; M/L, -0.2 mm; D/V -8.0 mm) and 
the other in the NAcc shell (A/P, +1.4 mm; M/L, +0.5 mm; D/V, -6.0 mm).  The 
cannulae were implanted ipsilaterally in the microdialysis experiments.  Microinjection  
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Figure 3.1:  Protocol for gestational drug treatments of offspring.  (A) Dams 
designated as Nic+EtOH on GD1, received EtOH gavages (4g/kg) beginning on GD2 and 
a nicotine mini-osmopump (2mg/kg/day) implantation on GD3. Postnatal exposure to 
EtOH began on PN2 with twice daily gavages of EtOH (4g/kg total) to each pup.  
Nicotine exposure was administered by replacing the nicotine pump (8g/kg) in the dam, 
so that the pups received nicotine through the dams’ milk. (B) Nic dams received daily 
gavages beginning GD2 of MD (4g/kg) and a nicotine mini-osmopump (2mg/kg/day) on 
GD3. Postnatal pup exposure with twice daily gavages of MD (4g/kg total) began on 
GD2 and a replacement nicotine mini-osmopump (8mg/kg/day) was inserted in their dam 
on GD3.   (C) EtOH dams received EtOH gavages (4g/kg) beginning on GD2 and a 
control mini-osmopump of water implanted on GD3. Postnatal exposure to EtOH began 
on PN2 with twice daily gavages of EtOH (4g/kg total) to each pup.  The control mini-
osmopump was replaced on GD3.  (D) PF dams received daily gavages beginning GD2 
of MD (4g/kg) and a control mini-osmopump of water on GD3. Postnatal pup exposure 
with twice daily gavages of MD (4g/kg total) began on GD2 and a replacement control 
mini-osmopump was inserted in their dam on GD3. 
A. 
 
 
 
 
B. 
 
 
 
 
 
C. 
 
 
 
 
 
D. 
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experiments require only one cannula in the VTA.  Each cannula was anchored with 2 
stainless steel screws and was covered with acrylic cement.  Animals recovered for 5 
days before implantation of a jugular cannula.  
 
 
Jugular Cannula Implantation:  Animals were anesthetized with a cocktail containing 
43mg/kg ketamine and 8.6 mg/kg xylazine  before being implanted with a catheter (PE 
90 and silastic tubing) into the right jugular vein and a plastic button (Instech, Plymouth 
Meeting, Pa., USA) posterior to the shoulder blades.  Animals for microdialysis 
experiments recovered for 2 days prior to experimentation. 
 
 
In Vivo Microdialysis:  Concentric microdialysis probes (2 mm for VTA and NAcc; MW 
cutoff 13,000 Da, outer diameter 235 um) were constructed in our laboratory.  
Microdialysis was performed at PND65-75; rats were placed into the alert-rat 
microdialysis chambers (CMA, Chelmsford, MA) located within an isolated room.  
Microdialysis probes were inserted into both NAcc and VTA guide cannulae.  Following 
insertion, probes were perfused (2ul/min) with artificial cerebral spinal fluid (αCSF; 
147mM NaCl, 2.7 mM KCl, 1.2 mM CaCl2, and 0.85 mM MgCl2 in polished water; 0.2 
mm filter sterilized and degassed) for 2 hours.  Subsequently, 15 min microdialysate 
samples are collected into plastic vials; 3 consecutive samples are collected to measure 
basal dopamine or GABA levels prior to drug administration.  Following baseline 
sampling the microdialysis experiments were conducted as follows.  For Nicotine-
stimulated neurotransmitter release measuring GABA in the VTA and DA in the NAcc, 
nicotine was administered after the third baseline sample.  Including the sample during 
the nicotine infusion, four 15 min samples were collected.   
 
 
HPLC and Electrochemical Detection of Neurotransmitters:  The procedure for DA 
detection was as previously described (Fu et al. 2000).  Briefly, mobile phase contained 
80mM sodium dihydrogen phosphate monohydrate, 5nM diamino ethanetetaacetic acid, 
2mM 1-octanesulfonic acid, 100ul/L triethylamine, and 10% Acetonitrile with pH 3.0 
(adjusted by phosphoric acid). An ESA 580 pump was used to perfuse mobile phase 
through an ODS C18 column (ESA, Chelmsford, MA) at a flow rate of 0.25ml/min. 
Electrochemical detection was performed at 220 mV with the gain at 1 nA and guard cell 
at 350 mV. Elution time for DA was approximately 5 minutes. Peak height was used for 
relative quantitation of DA. 
 
GABA was measured with a mobile phase containing 0.1 M disodium hydrogen 
phosphate in 10% methanol and 10% acetonitrile, pH 4.4 (adjusted by phosphoric acid). 
An ESA 580 pump was used to perfuse mobile phase through a LMS C18 column (ESA, 
Chelmsford, MA) at a flow rate of 2.0 ml/min. The derivatization stock solution was 
made by dissolving 22 mg of phthaldialdehyde (OPA) in 0.5 ml of 100% EtOH, and then 
adding 0.5 ml of 0.1M sodium sulfite and 9 ml of 0.1 M sodium tetraborate, pH 10.0. The 
working OPA solution was prepared daily by 1:30 diultion with Millipore water. For 
automated derivatization of a sample (with the ESA 542 Autosampler), 10 µl from the 
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VTA dialysate was mixed with 10 µl of working OPA solution. After 2 min, 17 µl of the 
mixture was injected onto the HPLC column and analyzed with an ESA Coulochem II 
5200A electrochemical detector, with ESA 5011A analytical cell. Elution time for GABA 
was approximately 6 min. Peak height was used for relative quantitation of GABA. 
 
 
Nicotine Self-Administration:  Adult male and female offspring (PND60-75) were 
allowed chronic, 23 h/d access to bar press for nicotine without prior training, shaping, or 
food deprivation, using our established model (Chen et al. 2007; Fu et al. 2001; Matta 
and Elberger 2007; Valentine et al. 1997).  Briefly, after implantation of a jugular 
cannula, rats were placed into individual operant chambers (Coulbourn Instr., Allentown, 
PA, USA) enclosed in ventilated, sound-attenuating environmental boxes.  The jugular 
line was connected to an injection pump (Med Associates, St. Albans, VT, USA) by a 
swivel (Instech, Plymouth Metting, PA, USA). Rats were given 3 d to recover from 
surgery while housed in individual operant chambers. Thereafter, rats were provided free 
access for 23 h daily (1 h daily is required for animal husbandry and downloading data) 
to two randomly assigned bars positioned 5 cm above the floor, each with a green light 
above signaling the availability of an injection. Pressing the active lever signaled the 
computer (Graphic State Notation software, Coulbourn Instr.) to activate a pump that 
delivered 30 µg/kg nicotine in a 50 µl heparinized saline bolus over 0.81 s on an FR1 
with a 7 s delay schedule; pressing the inactive lever had no programmed consequence. 
Self-administration day 1 was the first day when nicotine was made available, and the 
offspring were given 10 days unlimited free access to acquire nicotine self-administration 
on an FR1 schedule. 
 
As per our previously reported criteria for this open access model (Fu et al. 2001; Matta 
and Elberger 2007; Valentine et al. 1997), acquisition of nicotine self-administration 
behavior to maintenance criteria was defined as: (1) stabilization of the number of active 
bar presses on the final 3 d to within 15% variation, (2) active bar presses greater than 
inactive presses, and (3) active presses greater than 12/day.  
 
Microinjections of baclofen or vehicle (αCSF) into the VTA were completed 30 minutes 
prior to access to nicotine on the first 5 days of self-administration.  Injections of 50 
ng/250 nl of baclofen were made into the VTA over the course of 1 min and then the 
needle stayed in place for 2 minutes before withdrawal. 
 
 
Statistics:  Statistical analyses were completed with repeated measures ANOVA, one-
way ANOVA, and t-test where appropriate using SPSS software, with significance set at 
p<0.05. Values are presented as the mean + standard error of the mean (SEM) and the 
number of animals in each group was indicated within parentheses in the text and figures.  
 
 
 
 
 
24 
Results 
 
 
NAcc Shell DA Response to 30µg/kg i.v. Nicotine :  Baseline DA levels were not different 
between the treatment groups (p=0.34). Figure 3.2A shows that combined gestational 
exposure to Nic+EtOH increased nicotine-stimulated (30 µg) DA release in the NAcc 
shell of offspring compared to the groups treated with nicotine alone or ethanol and PF 
controls (F3,14: 4.26, p=.03).  Baseline GABA levels were similar in all treatment groups 
(p=0.92). Figure 3.2B shows that Nic+EtOH offspring released less nicotine-stimulated 
GABA in the VTA compared to PF offspring (F3,20: 4.5, p=0.01). 
 
 
Nicotine Self-Administration with Intra-VTA Baclofen Microinjection:  In agreement with 
our previous findings (Matta and Elberger 2007), gestational exposure to Nic+EtOH 
significantly augmented nicotine SA in the offspring compared to gestational PF controls 
(F1,100: 71.35, p<0.001; Figure 3.3). However, intra-VTA baclofen significantly reduced 
nicotine SA in Nic+EtOH offspring (F1,180: 16.89 and p<0.001) without affecting PF 
offspring. Indeed, baclofen reduced nicotine SA in Nic+EtOH offspring to the level 
observed in PF offspring, and there was no significant difference between the Nic+EtOH 
rats that received baclofen and the two control groups (i.e. PF offspring administered 
baclofen or vehicle). Therefore, the augmentation of nicotine SA induced by exposure to 
Nic+EtOH throughout gestation was abolished by intra-VTA baclofen. 
 
 
Discussion 
 
We determined whether VTA GABAergic neurotransmission is involved in the enhanced 
nicotine SA that is a consequence of gestational co-exposure to Nic+EtOH.  The results 
of the in vivo microdialysis experiment demonstrated that nicotine stimulated a 20% 
increase in DA levels within the NAcc shell of offspring previously exposed to only 
Nicotine, EtOH or PF, whereas, DA increased by 75% in Nic+EtOH offspring.  In 
addition, VTA GABA levels declined by 20% in Nicotine, EtOH, and PF offspring, while 
Nic+EtOH offspring showed a 50% reduction.  Additionally, Intra-VTA administration 
of baclofen abolished the enhanced nicotine SA seen in Nic+EtOH offspring, without 
affecting nicotine SA in PF offspring. 
 
Our lab had previously reported that adult male and female offspring with full-gestational 
exposure to the combination of nicotine and ethanol (Nic+EtOH) showed an increased 
nicotine SA compared to control offspring (i.e. those receiving gestational exposure to 
nicotine alone, EtOH alone, or PF) (Matta and Elberger 2007).  Our data suggest that the 
greater reduction in GABA release seen in Nic+EtOH offspring might be necessary to 
produce the greater increase of accumbal dopamine release also seen in these offspring.   
 
The reduction of VTA GABA release seen in Nic+EtOH offspring could occur because 
of a change in the sensitivity of GABA receptors following gestational drug exposure.  It  
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Figure 3.2:  Neurotransmitter release in response to 30µg of nicotine.  (A) Nicotine-
induced dopamine release in NAcc shell was significantly greater in PND60 Nic+EtOH 
offspring than PF (pair-fed). After 3 baseline microdialysate samples were collected, 
nicotine (30 µg/kg/10ul, i.v.) was injected into the jugular vein of freely moving rats. 
Dopamine was measured by HPLC with electrochemical detection.  Dopamine levels 
after nicotine injection were significantly increased in Nic+EtOH offspring compared to 
controls; F3,14: 4.26, p=.03. Baseline dopamine levels were unaffected by gestational 
treatment [PF vs. Nic+EtOH (mean±SEM): 1.33±0.087 pg/15ul and 1.54±0.086]. (B) 
Nicotine-induced GABA release in VTA was significantly greater in PND60 Nic+EtOH 
and EtOH offspring than PF (pair-fed). After 3 baseline microdialysate samples were 
collected, nicotine (30 ug/kg/10ul, i.v.) was injected into the jugular vein of freely 
moving rats. GABA was measured by HPLC with electrochemical detection.  GABA 
levels after nicotine injection of Nic+EtOH offspring were decreased to a significantly 
greater level compared to controls; F3,20: 4.5, p=0.01. 
A. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B. 
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Figure 3.3:  Nic+EtOH and PF offspring self-administration of 30µg/kg/inj of 
nicotine with and without microinjections of 50ng/250nl of baclofen.  Nic+EtOH 
offspring without baclofen had significantly higher responding for nicotine (F1,180: 16.89 
and p<0.001) over 10 days. 
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has been shown that evoked dopamine release in tissue after chronic subcutaneous 
nicotine injections (0.4 mg/kg) did not change with the application of a baclofen bath, 
whereas control animals had a reduction in dopamine release with a baclofen bath 
(Amantea and Bowery 2004).  Therefore, it is possible that the gestational nicotine 
exposure produced a long-term change in the sensitivity of VTA GABA receptors as part 
of their role to modulate NAcc DA release. 
 
The dopamine and GABA release in response to 30 µg/kg nicotine of gestational nicotine 
alone and EtOH alone offspring did not differ from PF control offspring. Therefore, these 
groups were not included in the SA experiment. However, these data indicate that at the 
low nicotine and alcohol doses that we used, the synergistic effect between gestational 
EtOH and nicotine exposure is responsible for the long-term consequence of 
neuroadapation and behavioral changes. Given the greater reduction of GABA release 
seen in Nic+EtOH offspring we hypothesized a possible reduction of GABA receptors in 
the VTA.  Studies have shown that prenatal ethanol exposure have reduced the number of 
GABA positive cells in rat and guinea pig (Bailey et al. 2004; Moore et al. 1998).  
 
The GABA-B agonist baclofen was chosen for the self-administration experiment since 
there is evidence-linking baclofen as a possible therapy for those attempting to quite 
smoking or for other drugs of abuse (Bowery 2006; Cousins et al. 2002).  Baclofen (50 
µM) infused into the VTA was previously shown to decrease accumbal dopamine release 
by 35% compared to saline (Westerink et al. 1996).  Experiments using animal models 
have displayed the ability of baclofen to lower nicotine self-administration responding 
(Corrigall et al. 2000; Fattore et al. 2002; Paterson et al. 2004).  Using our gestational 
model we were able to demonstrate that a low dose of baclofen was only able to disrupt 
the self-administration behavior of the Nic+EtOH offspring without altering the 
responding of PF offspring.  Baclofen microinjection into the VTA was given during the 
1 hour allotted for husbandry prior to the beginning of the 23-hour self-administration 
session. The half-life of baclofen is 1-5 hours in humans (Sallerin-Caute et al. 1991), 
which would argue that most of the reduction in SA is likely attributable to reduced 
nicotine intake early on during SA. The finding that intra-VTA baclofen did not affect 
nicotine responding in PF offspring suggested that the lowered responding of Nic+EtOH 
offspring with baclofen microinjections was not due to the sedative effects of baclofen. It 
has previously been shown that microinjection of baclofen into the VTA reduces 
dopamine in the NAcc (Kalivas 1993).  Other studies have also shown that low doses of 
baclofen do not alter responding for food (Le Foll et al. 2008; Paterson et al. 2004). 
Therefore, our data suggested that enhanced GABA neurotransmission in VTA is a 
potential mechanism to ameliorate the enhanced vulnerability to nicotine resulting from 
gestational drug exposure.  
 
In addition to the studies using animal models baclofen has also been involved in clinical 
studies for smoking cessation.  In one study, taking baclofen before smoking changed the 
individuals’ sensory association with a cigarette.  Those who took baclofen were more 
likely to associate smoking as negative or “harsh” (Cousins et al. 2001).  Preliminary 
studies have also shown that baclofen was able to reduce smoking compared to those 
taking a placebo (Franklin et al. 2009).  The clinical studies that demonstrate the possible 
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effectiveness that baclofen can alter smoking behavior may be connected with our 
experimental data that nicotine decreases GABA release in the VTA by 20% in control 
offspring.  Further reduction in normal VTA GABA inhibition at DA neurons would 
contribute to the increased smoking (SA) behavior.  Such dysinhibition would be offset 
by the baclofen by activation of GABA-B receptors. 
 
In conclusion, the offspring with full gestational Nic+EtOH exposure exhibited a greater 
reduction of GABA release in response to nicotine compared to PF offspring.   This 
marked reduction of VTA GABA in Nic+EtOH offspring in response to nicotine is not 
due to lack of GABA-B receptors. Rather, it is the hypo-GABAergic modulation of DA 
neurons that contributed to elevated accumbal DA release and subsequent enhanced 
nicotine SA behavior. 
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CHAPTER 4.    FULL-GESTATIONAL EXPOSURE TO NICOTINE AND 
ETHANOL AUGMENTS NICOTINE SELF-ADMINISTRATION BY ALTERING 
VENTRAL TEGMENTAL DOPAMINERGIC FUNCTION DUE TO NMDA 
RECEPTORS IN ADOLESCENT RATS‡ 
 
 
Introduction 
 
Tobacco is used by 26.5% of the US population over age 12 (Substance Abuse and 
Mental Health Services Administration 2012); 90% of habitual smokers begin before age 
18 (Kandel et al. 2007). During pregnancy, maternal smoking and ethanol intake 
negtively impact fetal brain development, resulting in behavioral disorders and smoking 
in offspring (Cornelius et al. 2007).  During teenage pregancy, 58% of smokers also 
drink alcohol (Cornelius et al. 2007).  Because of such concurrent usage throughout 
pregnancy and its impact on offspring, we developed a model of 3-trimester gestational 
exposure to both drugs (Matta and Elberger 2007); adult offspring exposed during 
gestation self-administer significantly more nicotine. 
 
The mesocorticolimbic pathway, essential for motivated drug-taking, includes ventral 
tegmental area (VTA), nucleus accumbens (NAcc), and medial prefrontal cortex (Koob 
and Nestler 1997). Critical VTA dopaminergic (DA) neurons projecting to NAcc are 
regulated by glutamatergic inputs primarily from prefrontal cortex (Mansvelder et al. 
2003).  N-methyl-D-aspartate (NMDA) receptors on DA neurons stimulate burst firing, 
increasing accumbal DA release (Amantea and Bowery 2004).  
 
Glutamatergic neurocircuitry, including VTA NMDA receptors essential for acquisition 
of appetitive behaviors, is developmentally regulated (Zellner et al. 2009).  For example, 
in early postnatal brain development, the predominant NR2B subunits are replaced by 
NR2A, altering NMDA receptor kinetics (Liu et al. 2004). This is delayed in cerebellar 
granule neurons by early postnatal exposure to ethanol (Snell et al. 2001). Additionally, 
peak expression of NR3A subunits, affecting synapse formation and synaptic spines, 
occurs during early postnatal (PN7-14) development (Henson et al. 2010).  Based on this 
exquisite timing of subunit expression and tuning of NMDA receptors and their role in 
addiction (Henson et al. 2010; Zellner et al. 2009), we hypothesized that concurrent 
gestational exposure to ethanol and nicotine would disrupt the control of VTA 
dopaminergic circuitry by NMDA receptors, augmenting nicotine self-administration 
(SA) in adolescent offspring.   
 
In vivo microdialysis was used to determine the responsiveness of accumbal DA and 
VTA glutamate to intra-VTA NMDA and systemic nicotine in adolescent offspring 
exposed to nicotine and ethanol in utero and early post-partum (i.e., during the human 3rd 
 
‡Roguski EE, Sharp BM, Chen H, Matta SG. Full-Gestational Exposure to Nicotine and 
Ethanol Augments Nicotine Self-Administration by Altering Ventral Tegmental 
Dopaminergic Function due to NMDA Receptors in Adolescent Rats. J Neurochem 
(2013) In Press 
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trimester equivalent of rat brain development) vs. pair-fed controls (PF). We also 
determined the efficacy of intra-VTA NMDA receptor blockade of nicotine-stimulated 
DA release and nicotine SA in both groups of offspring. Lastly, the expression of NMDA 
receptor mRNA transcripts and protein in VTA was measured.  
 
 
Materials and Methods 
 
 
Materials:  (−)-Nicotine hydrogen tartrate salt  (all doses calculated as free base) was 
purchased from Sigma (St Louis, MO).  NMDA was also purchased from Sigma (St 
Louis, MO).  SKF-83566 hydrobromide and DL-2-Amino-5-phosphonopentanoic acid 
sodium salt (AP5) were purchased from Tocris Bioscience (Bristol, UK). 
 
 
Animals and Gestational Exposure:  The model of gestational exposure to nicotine and 
ethanol in Sprague-Dawley rats was developed on site and described (Matta and Elberger 
2007). Briefly, female rats were group housed in order to acclimate to a reverse light 
cycle (11a.m. off; 11p.m. on) and then housed overnight (2 females to 1 male) until 
sperm positive. On the sperm positive day, dams were randomly assigned to either the 
Nic+EtOH or pair fed (PF) group (Figure  4.1).  PF dams were matched and fed 
according to the nutrition of the Nic+EtOH dam.  Gestational drug treatments are 
illustrated in Figure 4.1A and 4.1B.  The EtOH prenatal exposure was delivered by daily 
gavage of 4g/kg from gestational day 2 (GD2) until GD20.  The model utilizes a low 
dose of EtOH to mimic moderate binge drinking.  Nicotine was administered prenatally 
by implantation of a mini-osmopump delivering a constant 2 mg/kg dose (pH = 7.2-7.4).  
This dose simulates the blood levels achieved by 1-2 packs of cigarettes per day. PF dams 
were gavaged with an amount of maltose dextran (MD) that is equivalent to the calories 
of the EtOH gavage consumed by Nic+EtOH dams.  After the pups were born they 
received nicotine and ethanol treatments from postnatal day 2 (PN2) until PN12, in order 
to simulate drug exposure during the third trimester of human pregnancy.  The nicotine 
mini-osmopumps were replaced with another delivering 8mg/kg to the dams, whose 
breast milk transferred nicotine to the suckling pups. Ethanol was administered to pups 
by 2 gavages of 2g/kg each 30 minutes apart, whereas PF pups were gavaged twice daily 
with calorically matched maltose dextran.  All pups were weaned at PN21 and, thereafter, 
received standard amounts of food and water. They were used in the proposed 
experiments at PN41-45.  All procedures conducted in accordance with the NIH 
Guidelines for the Use and Care of Laboratory Animals and were approved by the 
Animal Care and Use Committee of the University of Tennessee Health Science Center.  
 
 
Cannula Implantation:  Using minor modifications of methods previously described (Fu 
et al. 2000, Kane et al. 2004), animals were anesthetized with a mixture of ketamine 
43mg/kg and xylazine 8.6 mg/kg and then stereotaxically implanted with two 20 GA 
(20mm) guide cannula targeted at the posterior VTA (A.P, -5.6 mm; M/L, -0.2 mm; D/V  
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Figure 4.1:  Protocol for offspring gestational drug treatments.  (A) Dams designated 
as Nic+EtOH on GD1, received EtOH gavages (4g/kg) beginning on GD2 and a nicotine 
mini-osmopump (2mg/kg/day) implantation on GD3.  Postnatal exposure to EtOH began 
on PN2 with twice daily gavages of EtOH (4g/kg total) to each pup.  Nicotine exposure 
was administered by replacing the nicotine pump (8g/kg) in the dam, so that the pups 
received nicotine through the dams’ milk.  (B) PF dams received daily gavages beginning 
GD2 of MD (4g/kg) and a control mini-osmopump of water on GD2.  Postnatal pup 
exposure with twice daily gavages of MD (4g/kg total) began on PN2 and a replacement 
control mini-osmopump was inserted in their dam on PN2.  All offspring are weaned on 
PN21. 
 
A. 
 
 
 
 
 
B. 
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-8.0 mm) and the NAcc shell (A/P, +1.4 mm; M/L, +0.5 mm; D/V, -6.0 mm). The 
coordinates were adjusted for adolescent animals by body weight (AP=adultAP-
0.005×(300-body weight); ML=adultML/2; DV=adultDV-(approximately 0.5-1.0). For 
microinjection experiments, only VTA was cannulated.  Animals recovered for 5 d before 
implantation of a jugular cannula. 
 
 
In Vivo Microdialysis:  As previously described (Fu et al. 2000; Kane et al. 2004), 
concentric microdialysis probes (2 mm for VTA and NAcc; MW cutoff 13,000 Da, outer 
diameter 235 um) were constructed in our laboratory.  For microdialysis experiments, 
performed at PN45-55, rats were placed into alert-rat microdialysis chambers (CMA, 
Chelmsford, MA), located within an isolation room, and microdialysis probes were 
inserted into both NAcc and VTA guide cannulae. Probes were then perfused (2µl/min) 
with artificial cerebrospinal fluid (αCSF; 147mM NaCl, 2.7 mM KCl, 1.2 mM CaCl2, and 
0.85 mM MgCl2 in polished water; pH to 7.2-7.4, sterilized through 0.2 mm filters and 
degassed) for 2 hours.  After acclimation to the microdialysis probes, samples were 
collected into plastic vials every twenty minutes until the end of the experiment.   Up to 4 
rats were run concurrently with an equal number of Nic+EtOH and PF offspring.  For 
reverse dialysis, syringes were changed 20 minutes prior to drug infusion into the VTA 
(length of time at 2ul/min for the solution to fill the microdialysis probe). 
 
 
Protocols for Microdialysis Experiments:   
 
1. NMDA Dose Response Experiment:  NMDA and KCl were dissolved in aCSF 
(NMDA: 200µM and 500µM; KCl: 100mM) and reverse dialyzed into VTA 
during the experiment.  Each concentration of agent was set to pH 7.4, 
degassed, and then drawn into a 2.5mL gastight Hamilton syringe.  DA 
samples were analyzed from 5 Nic+EtOH and 6 PF offspring.  Glutamate 
samples were analyzed from 9 Nic+EtOH and 7 PF offspring.  Three 
consecutive baseline samples (20 min each) were collected during reverse 
dialysis of aCSF, followed by 3 samples during reverse dialysis of 200uM 
NMDA, 2 samples during delivery of aCSF, 3 samples during reverse dialysis 
of 500uM NMDA, 2 samples during αCSF, and finally 3 samples during 
reverse dialysis of 100mM KCl.  
 
2. Antagonism of D1 Receptors in the VTA followed by NMDA: D1 receptor 
antagonist, SKF-83566 (100µM), and NMDA (200µM and 500µM) were 
dissolved in αCSF for reverse dialysis. DA samples were analyzed from 7 
Nic+EtOH and 5 PF offspring at 200µM NMDA and 8 Nic+EtOH and 10 PF 
offspring at 500µM NMDA.  Glutamate samples were analyzed from 9 
Nic+EtOH and 13 PF offspring at 200µM NMDA and 5 Nic+EtOH and 8 PF 
offspring at 500µM NMDA.  Three baseline samples (20 min each) were 
collected during reverse dialysis of αCSF, followed by 2 samples during 
reverse dialysis of SKF-83566, and then 3 samples during delivery of NMDA 
at either the 200µM or 500µM concentration. 
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3. 30µM Nicotine i.v. with NMDA Receptor Antagonism: Nicotine was dissolved 
in saline to deliver 30µg/kg (free base) in 10µL (pH of 7.4).  AP5 for reverse 
dialysis was dissolved in αCSF at 75µM and 200µM (pH 7.4). DA samples 
were analyzed from 6 Nic+EtOH and 6 PF offspring at 0µM AP5 (αCSF), 4 
Nic+EtOH and 5 PF offspring at 75µM AP5, and 5 Nic+EtOH and 7 PF 
offspring at 200µM AP5.  Glutamate samples were analyzed from 5 Nic+EtOH 
and 4 PF offspring at 0µM AP5, 4 Nic+EtOH and 5 PF offspring at 75µM 
AP5, and 8 Nic+EtOH and 3 PF offspring at 200µM AP5.  Three baseline 
samples were collected during reverse dialysis of αCSF and then the last 6 
samples were collected during reverse dialysis of AP5 (0µM, 75µM, or 
200µM).  At the start of the 5th sample, nicotine (30µg in 10µL) was injected 
i.v.  
 
 
HPLC with Electrochemical Detection:  The procedure for detection of dopamine (DA) 
and excitatory amino acids (e.g., glutamate) was previously described (Fu et al. 2000).  
Briefly, for DA, the mobile phase contained 80mM sodium dihydrogen phosphate 
monohydrate, 5nM diamino ethanetetraacetic acid, 2mM 1-octanesulfonic acid, 100µl/L 
triethylamine, and 10% acetonitrile, pH 3.0 (adjusted with phosphoric acid). An ESA 580 
pump perfused mobile phase through a 15 cm 3 x 4.6 mm ODS C18 column (ESA, 
Chelmsford, MA) at 0.25ml/min, and DA was detected at 220 mV with gain at 1 nA and 
guard cell at 350 mV.  For glutamate, a mobile phase containing 0.1 M disodium 
hydrogen phosphate in 10% methanol and 10% acetonitrile, pH 4.4. Perfused into a 15 
cm 3 x 4.6 mm ODS C18 column (ESA, Chelmsford, MA) at 1.0 ml/min. 
Phthaldialdehyde (OPA) stock solution was prepared from 22 mg OPA in 0.5 ml of 100% 
EtOH, followed by the addition of 0.5 ml sodium sulfite 0.1M and 9 ml sodium 
tetraborate 0.1 M, pH 10.0. A working OPA solution (1:30 dilution in water) was 
prepared daily and used for automated sample derivatization (ESA 542 Autosampler), in 
which 2 µl VTA dialysate was diluted with 8ul polished HPLC grade water and mixed 
with 10 µl of working OPA for 2 min, and then 17 µl was injected on column and 
analyzed with an ESA Coulochem II 5200A detector (5011A analytical cell). 
 
 
Brain Punches and Tissue Preparation:  Offspring at PN45 were anesthetized with 
isoflurane and decapitated to obtain brain tissues for qRT-PCR (Nic+EtOH n=7, PF n=7) 
and Western blot analysis (Nic+EtOH n=15, PF n=9). The brain punch procedure and 
tissue preparation were performed according to our established protocol (Wang et al. 
2007). Briefly, rats were anesthetized with isoflurane, decapitated, and brains were 
removed and stored at -800C. Frozen brain sections, 0.7 mm thick, were obtained using 
razor blades and a stage, designed and assembled in our laboratory. The VTA was 
punched according to the atlas of Paxinos and Watson (1986), using a 20-gauge syringe 
adapter. Dissected tissues were frozen on dry ice and stored at –80°C.  
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RNA Isolation, cDNA Synthesis, and qtPCR.:  Total RNA was extracted, using RNAeasy 
Lipid Tissue Mini Kit (Qiagen), and reverse transcribed into cDNA with Superscript III 
(Invitrogen), using oligo(dT) 18 primers according to the manufacturer’s instructions. 
qtPCR was performed by using the following primers: NR1-Forward: 
acatatgtgagaaatacaacctttgg, NR1-Reverse: cttccgggacatgagcag, NR2A-Forward: 
agcagccgggtagagagg, NR2A-Reverse: tcccccttttcagagtacacc, NR3A-Forward: 
gctttgccgtcactagact, NR3A-Reverse: atgcacaacagcacgaagag, HPRT-Forward: 
gaccggttctgtcatgtcg, HPRT-Reverse: acctggttcatcatcactaatcac, YWHAZ-Forward: 
gcagttactgagagacaacttgaca, YWHAZ-Reverse: tggaaggccggttaatttt, PGK1-Forward: 
gcaaagactggccaagctac, PGK1-Reverse: gcctcagcatatttcttactgct.  Quantification was 
performed using the comparative CT method (ΔΔ CT). Results are expressed relative to 
the levels of housekeeping genes: HPRT, YWHAZ and PGK1. 
 
 
Western Blot Analysis:  To determine ionotropic glutamate receptor expression levels 
after gestational drug exposure, alternating samples from same brain region of each 
treatment group (i.e., Nic+EtOH vs. PF) were loaded on the same gel.  
 
The procedure for Western immunoblotting was previously described by us (Wang et al. 
2007) . Briefly, tissue samples were sonicated on ice water in 2% sodium dodecyl sulfate 
(SDS) for 30s with 10 s bursts and then centrifuged at 800 × g for 5 min. Protein 
concentrations were measured using the bicinchoninic acid assay (Pierce, Rockford, IL).  
Samples were diluted in Laemmli buffer (Bio-Rad, Hercules, CA) at a ratio of 1:2, boiled 
for 5 min, loaded, and then separated on 10% Tris-HCl ready gels (Bio-Rad, Hercules, 
CA) in a buffer containing 0.1% SDS, 192mM glycine, and 25mM Tris, pH 8.3. Proteins 
were transferred to polyvinylidene difluoride (PVDF) membranes (Bio-Rad, Hercules, 
CA) in a buffer containing 192mM glycine, 20% methanol, and 25mM Tris, pH 8.3. 
Membranes were then washed in Tris-buffered saline with Tween-20 (TBST) and 
blocked overnight with agitation in 5% nonfat dried milk at 4°C. Based on molecular 
weight (MW) differences between NMDA receptor subunits and b-actin, blots were cut 
into 2 sections by visualizing the MW markers: upper blots were used to detect NMDA 
receptor subunits and lower blots for b-actin. Each section contained alternating samples 
from the Nic+EtOH and PF offspring. Blots were incubated in blocking solution for 2h at 
RT or overnight at 4C with antibodies against b -actin (1:1000; Sigma, St Louis, MO), 
NMDA receptor subunit 1 (NR1; 1:300 ; Santa Cruz, CA), NR2A (1:200; Santa Cruz) 
and NR2B (1:200; Santa Cruz), washed in TBST and then incubated in horseradish 
peroxidase-conjugated secondary antibody (1:1000, Santa Cruz, CA). Target proteins 
were visualized by Supersignal (Pierce, Rockford, IL) followed by imaging with a Bio-
Rad ChemiDoc and quantitation by Quantity One software (Bio-Rad, Hercules, CA).   
 
 
Nicotine Self-Administration:  Adolescent offspring (PN 41-55) were allowed chronic, 
almost unlimited (i.e., 23 h/d) access to bar press for nicotine without prior training, 
shaping, or food deprivation, using our established model (Matta and Elberger 2007; 
Valentine et al. 1997).  Briefly, after implantation of a jugular cannula, rats were placed 
into individual operant chambers (Coulbourn Instr., Allentown, PA, USA) enclosed in 
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ventilated, sound-attenuating environmental boxes.  The jugular line was connected to a 
microinjection pump (Med Associates, St. Albans, VT, USA) by a single channel swivel 
(Instech, Plymouth Meeting, PA, USA). Rats were given 3 d to recover from surgery 
while housed in individual operant chambers. Thereafter, rats were provided free access 
for 23 h daily (1 h daily is required for animal husbandry and downloading data) to two 
randomly assigned bars positioned 5 cm above the floor, each with a green light above 
signaling the availability of an injection. Pressing the active lever signaled the computer 
(Graphic State Notation software, Coulbourn Instr.) to activate a pump that delivered 
30µg/kg nicotine in a 50-µl bolus, containing heparin, over 0.81 s on an FR1 schedule 
with a 7 s time-out; pressing the inactive lever had no programmed consequence. Self-
administration day 1 (SA d1) was the first day when nicotine was made available, and the 
offspring were given 10 d unlimited free access to acquire nicotine SA on an FR1 
schedule. 
 
As per our previously reported criteria for this prolonged access model (Fu et al. 2001; 
Matta and Elberger 2007; Valentine et al. 1997), acquisition of stable nicotine SA 
behavior was defined as: (1) <15% variation in active bar presses during the final 3 d of 
SA, (2) active bar presses > inactive presses, and (3) active presses > 12/day.  
 
 
Nicotine Self-Administration Experimental Protocol:  Nic+EtOH offspring were placed 
into individual operant chambers following surgery to insert a cannula into the left 
jugular vein.  After surgery offspring were randomly designated to receive an intra-VTA 
microinjection of either AP5 or αCSF. AP5 was injected into the VTA of 7 Nic+EtOH 
and 6 PF offspring, while αCSF was injected into 6 Nic+EtOH and 8 PF offspring.  
Microinjections into VTA were completed 30 min prior to access to nicotine [30µg/kg 
dissolved in heparin-saline (200units/mL) pH 7.2-7.4] on the first 5 d of SA.  AP5 (500ng 
AP5/250nl αCSF) or αCSF was injected over 1 min and the needle remained in place for 
2 more min.  The rats remained in the operant chambers and were undisturbed except for 
animal husbandry. 
 
 
Statistics:  Statistical analysis, using SPSS, was performed with three-way ANOVA, two-
way ANOVA, one-way ANOVA, and repeated measures ANOVA where appropriate, 
with significance set at p<0.05. Values are mean + standard error (SEM).  HPLC values 
were calculated using peak heights obtained from chromatograms using PowerChrom 
(eDAQ).  The analyte levels present in the first 3 baseline samples from each animal were 
averaged and the levels of analyte in all subsequent samples were expressed as a 
percentage of this baseline level.   
 
 
Results 
 
 
Effects of Intra-VTA NMDA on DA in NAcc Shell and Glutamate in VTA :  Peak 
accumbal DA levels in response to reverse dialysis of 200µM NMDA, 500µM NMDA, 
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and 100mM KCl were detected 40-60 min (i.e., 3rd sample) after the administration of 
each agent (Figure 4.2A).  NMDA stimulated significantly greater peak DA levels in 
Nic+EtOH vs. PF offspring (Figure 4.2B; 200µM and 500µM NMDA, F1,9:6.29 p=0.03 
and F1,9:6.69 p=0.03  respectively), whereas the effects of KCl were similar in both 
groups. 
  
Peak VTA glutamate levels followed the same pattern (Figure 4.2C), in that Nic+EtOH 
offspring had significantly higher peak levels (Figure 4.2D) in response to 200µM 
(F1,14:6.64 p=0.02) and 500µM NMDA (F1,14:15.93 p=0.001), while glutamate responses 
to KCl were not different between the two cohorts. Baseline levels of both DA 
(Nic+EtOH vs. PF: 1.40±0.24 vs. 1.26±0.16 pg/20µl) and glutamate (Nic+EtOH vs. PF: 
47.58±4.39 vs. 43.00±5.39 pg/µl) were similar in the two cohorts.  
 
 
Effects of Intra-VTA D1 Receptor Antagonist SKF-83566 on NMDA-Stimulated Release 
of DA in NAcc Shell and Glutamate in VTA:  In Figure 4.3A, following administration of 
D1 antagonist, SKF-83566, reverse dialysis of NMDA (200µM or 500µM) into the VTA 
did not stimulate NAcc DA release compared to baseline.  Baseline DA levels in 
Nic+EtOH and PF groups were unaffected by the intra-VTA infusion of SKF-83566 
(1.37±0.09 vs. 1.43±0.18 pg/20µl, respectively).  
 
Figure 4.3B displays the levels of VTA glutamate, which were unchanged compared to 
baselines following infusion of SKF-83566 into the VTA.  Subsequent, intra-VTA 
delivery of NMDA (200µM or 500µM) did not stimulate glutamate release compared to 
baselines in both gestational treatment groups.  The baseline levels of glutamate in 
Nic+EtOH offspring were similar to PF (43.92±5.83 vs. 46.57±3.64 pg/µl, respectively). 
 
 
Effects of NMDA Receptor Antagonist AP5 on DA and Glutamate Levels Stimulated by 
Nicotine:  In the absence of AP5 (Figure 4.4A), nicotine (30ug, i.v.) significantly 
stimulated NAcc DA release compared to baselines in both Nic+EtOH and PF offspring 
(F1,40: 8.55, p=0.006 and F1,34: 6.76, p=0.014, respectively). DA release was greater in 
Nic+EtOH offspring (approximately 50% increase over baseline) compared to PF 
offspring (approximately 20% increase over baseline; F1,11:8.36; p=0.02).  In contrast, 
VTA glutamate levels in both cohorts were unaffected by this dose of nicotine (Figure 
4.4B). 
 
Figure 4.5 shows the effects of intra-VTA AP5 on NAcc DA and VTA glutamate 
following i.v. nicotine.  Microinjections of AP5 into the VTA did not significantly alter 
baseline NAcc DA levels.  Compared to AP5 0µM (same data as in Fig. 4A), both 75µM 
and 200µM AP5 inhibited nicotine-stimulated DA release in Nic+EtOH offspring 
(F2,13:13.87, p=0.001; Figure 4.5A). Although DA levels in the 3 PF treatment groups 
shown in Figure 4.5B were not significantly different from each other, nicotine-
stimulated DA release was only significant in the absence of AP5 (i.e., AP5 AP5 0µM; 
same data as in Figure 4.4A). In addition, baseline DA levels were not different in the 3 
PF treatment groups (p=0.96).   
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Figure 4.2:  Effects of intra-VTA NMDA on NAcc shell DA and VTA glutamate 
levels. NAcc shell DA (A) and VTA glutamate (C) were measured following reverse 
dialysis of 200µM NMDA (N 200-1,2,3), 500µM NMDA (N 500-1,2,3) and 100mM KCl 
(KCl 1,2,3), each for 60 min into the VTA.  Sequential 20 min-samples were collected 
(i.e., beginning at each time mark in Figure 4.2A and 4.2C) until the end of the 
experiment.  Neither baseline DA nor glutamate levels were significantly different 
between Nic+EtOH and PF offspring (DA: 1.40±0.4 vs. 1.26±0.16 pg/20µl, respectively; 
glutamate: 47.58±4.39 vs. 43.00±5.39 pg/µl, respectively). Peak levels of DA (B) present 
in the third sample collected after initiating reverse dialysis with each agent were 
significantly higher for Nic+EtOH (n=6) compared to PF (n=5) at 200µM (F1,9:6.29 
p=0.03) and  500µM (F1,9:6.69 p=0.03) of NMDA.  Peak glutamate levels (D) were 
significantly greater in Nic+EtOH (n=9) offspring compared to PF (n=7) in response to 
NMDA 200µM (F1,14:6.64 p=0.02) and 500µM (F1,14:15.93 p=0.001).  There were no 
significant differences in responses to 100mM KCl between the treatment groups. 
A. 
 
 
 
 
 
 
 
 
 
 
 
 
B. 
C. 
 
 
 
 
 
 
 
 
 
 
 
 
D. 
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Figure 4.3:  Effects of NMDA exposure following pretreatment with D1 receptor 
antagonist SKF-83566 on NAcc shell DA and VTA glutamate levels.  NAcc DA (A) 
and VTA glutamate (B) were measured during reverse dialysis of 100uM SKF-83566 
(SKF1,2) followed by either 200µM or 500µM NMDA (NMDA1,2,3) into the VTA.  (A) 
Following NMDA, DA did not increase for either treatment group.  Baseline DA levels 
were not significantly different between Nic+EtOH (200µM: n=7 and 500µM: n=8) and 
PF (200µM: n=5 and 500µM: n=10) offspring (1.37±0.09 vs. 1.43±0.18 pg/20µl, 
respectively).   (B)  Similarly, VTA glutamate was unaffected by NMDA in  Nic+EtOH 
(200µM: n=9 and 500µM: n=5)  and PF (200µM: n=13 and 500µM: n=8), additionally 
baseline glutamate levels were not different (43.92±5.83 vs. 46.57±3.64 pg/µl, 
respectively). 
 
 
B. 
A. 
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Figure 4.4:  Effects of nicotine on NAcc DA and VTA glutamate in Nic+EtOH and 
PF offspring.  Nicotine 30ug was injected i.v. at the beginning of the 5th sample 
collection (120min). (A)  Nic+EtOH (n=6) offspring had a significantly greater accumbal 
DA response to nicotine compared to PF (n=6; F1,11:8.36; p=0.02).  Baseline DA levels 
were not significantly different between Nic+EtOH and PF (1.50±0.21 vs. 1.56±0.05 
pg/20µl, respectively).  Accumbal DA release in response to nicotine was significantly 
increased from baseline levels for both Nic+EtOH (F1,40: 8.55, p=0.006) and PF (F1,34: 
6.76, p=0.014). (B)  VTA glutamate was unaffected by nicotine in both Nic+EtOH (n=5) 
and PF (n=4) offspring, and baseline glutamate levels were not different (37.68±6.97 vs. 
40.59±8.33 pg/µl, respectively). 
A.                                                                    B. 
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Figure 4.5:  Effects of AP5 on nicotine-stimulated NAcc DA and VTA glutamate 
release in Nic+EtOH and PF offspring.   Nic+EtOH and PF offspring received various 
doses of AP5 prior to 30µg nicotine i.v. (A) DA release from Nic+EtOH offspring was 
significant from baseline F1,40: 8.55, p=0.006 without infusion of AP5 (0µM n=6).  AP5 
75µM (n=4) and 200µM (n=5) blocked nicotine-stimulated DA release in Nic+EtOH 
offspring. Nicotine-stimulated DA release (B) in PF treated with AP5 0µM (n=6), 75µM 
(n=5), and 200µM (n=7) did not differ significantly. However, only accumbal DA release 
in PF offspring produced a significant response from baseline (F1,34: 6.76, p=0.014). 
Baseline DA levels were not significantly different between Nic+EtOH and PF offspring 
(1.53±0.18 vs. 1.38±0.20 pg/20µl).  Nicotine did not stimulate significant glutamate 
release in VTA of Nic+EtOH (C). In the Nic+EtOH group, treatment with AP5 200µM 
(n=8) followed by i.v. nicotine significantly reduced glutamate levels (F2,17:6.98; p=0.01) 
compared to 0µM (n=5) and 75µM (n=5).   PF offspring (D) did not show a change in 
glutamate in response to nicotine with AP5 infusion at 0µM (n=4), 75µM (n=4), or 
200µM (n=3). Baseline glutamate levels were not significantly different between 
Nic+EtOH and PF offspring (41.28±3.73 vs. 41.96±5.98 pg/µl, respectively). 
 
 
A. 
 
 
 
 
 
 
 
 
 
 
 
 
C. 
B. 
 
 
 
 
 
 
 
 
 
 
 
 
D. 
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In Nic+EtOH offspring, neither dose of AP5 per se affected VTA glutamate levels,  
although glutamate significantly decreased after nicotine in the group receiving 200µM 
AP5 (F2,17:6.98; p=0.01; Figure 4.5C). Similarly, neither AP5 nor nicotine affected VTA 
glutamate levels in PF offspring (Figure 4.5D). 
 
 
Effects of Gestational Nicotine and Ethanol Exposure on mRNA Transcript Expression of 
NMDA Receptor Subunits in VTA:  Since gestational drug exposure occurred during 
critical phases of brain development, NMDA receptor gene expression was measured in 
VTA from adolescent offspring (PN45).  Figure 4.6 demonstrates that gestational 
exposure to Nic+EtOH did not alter gene expression levels of VTA NMDA receptor 
subunits compared to PF controls (NR1: p=0.42, NR2A: p=0.81, NR2B: p=0.7, and 
NR3A: p=0.55). 
 
 
Effects of Gestational Nicotine and Ethanol Exposure on NMDA Receptor Subunit 
Protein Expression in VTA:  Western immunoblottting of VTA extracts from PN45 
offspring was done to determine if exposure to Nic+EtOH altered the relative amount of 
NMDA receptor subunits during adolescence.    Figure 4.7 shows that NMDA receptor 
subunit expression in Nic+EtOH and PF offspring did not differ (NR1: p=0.37, NR2A: 
p=0.57, and NR2B: p=0.53). 
 
 
Effect of NMDA Receptor Antagonist AP5 on Nicotine Self-Administration:  We have 
previously shown that nicotine SA is amplified in adult Nic+EtOH compared to PF 
offspring (Matta and Elberger 2007).  In the experiment shown in Figure 4.8, our aim 
was to determine whether AP5 would differentially inhibit the acquisition of nicotine SA 
by altering this behavior in Nic+EtOH offspring without affecting PF offspring. 
Adolescent Nic+EtOH offspring that received a daily intra-VTA microinjection of 
vehicle (i.e., α-CSF) showed enhanced nicotine SA behavior compared to PF offspring 
(Two-way ANOVA: gestational treatment, F1,120: 51.27, p=0.000001).  Daily 
microinjections of AP5 reduced the level of nicotine SA acquired by Nic+EtOH 
offspring, without affecting PF rats (Three-way ANOVA: gestational treatment × AP5, 
F1,220: 18.04, p=0.000032).  Indeed, nicotine SA behavior in Nic+EtOH offspring 
receiving AP5 was not different from vehicle-treated PF offspring. Therefore, AP5 
specifically prevented acquisition of the component of nicotine SA behavior that was 
enhanced by gestational exposure to Nic+EtOH. 
 
 
Discussion 
 
Glutamatergic innervation of VTA is vital to the regulation of DA neurons projecting to 
nucleus accumbens that mediate the rewarding properties of nicotine and other abused 
drugs (Geisler and Wise 2008). These experiments demonstrate that adolescent offspring 
with gestational exposure to Nic+EtOH are more sensitive to intra-VTA NMDA than PF 
offspring.  Thus, NMDA induced greater increases in accumbal DA and VTA glutamate  
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Figure 4.6:  Effects of gestational drug exposure on NMDA receptor subunit 
transcript expression by qt-PCR. VTA brain punches were taken from adolescent (P45) 
Nic+EtOH (n=7) and PF offspring (n=7).  Gestational Nic+EtOH exposure did not alter 
the levels of mRNA transcripts encoding NMDA receptor subunits (NR1: p=0.42, NR2A: 
p=0.81, NR2B: p=0.7, and NR3A: p=0.55).  
 
 
 
 
 
Figure 4.7:  Effects of gestational Nic+EtOH exposure on NMDA receptor subunit 
protein expression. VTA brain punches were taken from adolescent (P45) Nic+EtOH 
(n=15) and PF (n=9) offspring. NMDA receptor subunit protein levels were not changed 
in Nic+EtOH offspring compared to PF (NR1: p=0.37, NR2A: p=0.57, and NR2B: 
p=0.53. 
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Figure 4.8:  Effects of AP5 on nicotine SA in adolescent Nic+EtOH and PF 
offspring. Nicotine SA (30µg/kg/inj) was acquired by both groups of adolescent 
offspring that received AP5 (500ng/250nl) or vehicle microinjections into VTA at the 
beginning of each SA session on d 1-5.  In the absence of AP5, Nic+EtOH offspring 
showed significantly higher responding for nicotine over the entire 10 days compared to 
PF, Nic+EtOH+AP5, and PF+AP5 offspring (F1,220:18.04, p=0.000032; interaction 
between gestational drug treatment and AP5 microinjection). 
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in adolescent rats exposed to Nic+EtOH in utero. In addition, nicotine stimulated higher 
levels of accumbal DA in these offspring and they acquired more robust nicotine SA.   
Consistent with their enhanced sensitivity to NMDA, nicotine SA by adolescent 
Nic+EtOH offspring was reduced by an NMDA receptor antagonist, whereas PF controls 
were unaffected. Indeed, intra-VTA AP5 completely reversed the enhanced nicotine SA, 
resulting in levels observed in untreated PF adolescents. Therefore, during adolescence, 
NMDA receptor-dependent activation of VTA DA neurons projecting to NAcc shell is 
altered by gestational exposure to Nic+EtOH. 
 
The role that NMDA receptors play in the mesocorticolimbic reward pathway has long 
been recognized (Jain et al. 2008; Mansvelder et al. 2003; Zellner and Ranaldi 2010). We 
previously demonstrated that VTA glutamate release induced by nicotine is correlated 
with accumbal DA release in untreated rats (Fu et al. 2000).   However, relatively high 
dose i.v. nicotine was necessary to detect a significant increase in VTA glutamate release 
(Fu et al. 2000).  Therefore, in the current study, we expected a relatively nominal release 
of glutamate after 30µg nicotine, although this dose robustly reinforces nicotine SA 
behavior (Valentine et al.), especially in Nic+EtOH offspring. Thus, by utilizing this dose 
of nicotine (i.e., 30µg), the effects of nicotine on neurotransmitters and behavior can be 
directly compared. 
 
We found that 30µg nicotine stimulated significantly higher levels of accumbal DA in 
Nic+EtOH than PF offspring.  In both of these cohorts, the efficacy of AP5 showed that 
signaling through NMDA receptors in VTA is required for nicotine-induced DA release, 
even though VTA glutamate levels were unaffected by nicotine. This may indicate that 
tonic synaptic levels of VTA glutamate are sufficient to activate dopamine neurons via 
NMDA receptors. Alternatively, it may simply indicate that stimulation by this low dose 
of nicotine was not sufficient to detect the synaptic overflow of glutamate. In previous 
studies, (Fu et al. 2000), we also demonstrated the role of NMDA receptors by infusing 
an NMDA antagonist into the VTA, which diminished accumbal dopamine release in 
response to nicotine.   Another study showed that nicotine enhanced intracranial self-
stimulation and this enhancement was blocked by an NMDA receptor antagonist (Kenny 
et al. 2009).  In VTA slices, AP5 also was able to reduce but not completely block the 
excitatory response of nicotine (Grillner and Svensson 2000).  
 
As to the mechanism underlying the release of VTA glutamate by NMDA, It is known 
that activation of VTA D1 receptors stimulates the local release of glutamate (Kalivas 
and Duffy 1995). Therefore, we hypothesized that elevation of accumbal DA by NMDA 
would be accompanied by release of VTA DA and activation of D1 receptors. The 
release of VTA DA by nicotine has been reported ((Erhardt et al. 2002). The current 
studies show that antagonism of VTA D1 receptors blocked the VTA glutamate response 
to NMDA, implicating the release of VTA DA by NMDA in the stimulation of D1 
receptors.  Unexpectedly, D1 receptor antagonism also inhibited accumbal DA release in 
response to NMDA, suggesting that activation of VTA NMDA receptors is insufficient to 
stimulate DA release and that other populations of glutamate receptors are targeted by 
glutamate released in response to VTA DA. AMPA receptors are potential targets of this 
glutamate.  One study, using VTA slices, showed that 6-cyano-7-nitroquinoxaline-2,3-
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dione (i.e., CNQX), an AMPA receptor antagonist, reduced DA neuron firing induced by 
nicotine (Grillner and Svensson 2000). Moreover, the AMPA receptor antagonist 
[1,2,3,4-tetrahydro-7-morpholinyl-2,3-dioxo-6-(fluoro-methyl) quinoxalin-1-yl] 
methylphosphonate (i.e., ZK200775; 3.0mg/kg, i.p.) blocked nicotine-stimulated NAcc 
dopamine release in a dose dependent manner (Kosowski et al. 2004). In contrast, we 
have previously shown by microdialysis that intra-VTA CNQX did not alter nicotine-
stimulated NAcc DA release (Fu et al. 2000).  In addition, it was found that AMPA 
receptor antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione 
(NBQX) did not alter nicotine SA behavior (Kenny et al. 2009).  In face of this 
conflicting data, the role of AMPA receptors in nicotine-stimulated NAcc dopamine 
release and nicotine SA remains unclear. 
 
The expression of NMDA receptor subunits in VTA was measured to gain further insight 
into the function of NMDA receptors. The expression of the NR2A and NR2B receptor 
subunits, in particular, demonstrate a delayed “developmental switch” induced by in vitro 
exposure to ethanol (Snell et al. 2001).  In another study, chronic exposure to ethanol 
followed by withdrawal induced long-term facilitation in the dorsomedial striatum of 
adult rats that was mediated by NMDA receptors containing NR2B subunits (Wang et al. 
2010).  Although withdrawal after ethanol exposure increased NMDA receptor activity 
(i.e., facilitation) in dorsomedial but not dorsolateral striatum, the expression of NR2B 
subunits did not differ between these two brain regions. In alignment with this report, our 
results demonstrate that both the number of transcripts encoding specific NMDA subunits 
and receptor subunit expression, detected by immunoblotting, were unaffected by 
gestational exposure to Nic+EtOH.  Our lab has also shown that expression of NR2A and 
NR2B receptor subunits was unchanged after chronic nicotine SA in adult Lewis rats 
(Wang et al. 2007). Taken together, these studies indicate that chronic exposure to 
ethanol followed by withdrawal can alter the long-term function of NMDA receptors 
containing specific receptor subunits (e.g., NR2B), without affecting expression levels of 
the receptor subunits.   
 
These experiments show that AP5 antagonism of VTA NMDA receptors only blocked 
the fraction of nicotine SA behavior that was augmented by gestational exposure to 
Nic+EtOH.  The unblocked fraction of nicotine SA was equivalent to nicotine SA in PF, 
which itself was unaffected by AP5.  Despite these clear behavioral differences in 
responsiveness to AP5, accumbal DA release to a single dose of nicotine was abolished 
in both gestational cohorts.  This discrepancy most likely reflects the relatively limited 
efficacy of a single daily intra-VTA injection of AP5 in our prolonged access model (i.e., 
23 h access to nicotine SA).  Indeed, AP5 inhibited the acquisition of food-reinforced 
behavior in 1 h operant sessions (Zellner et al. 2009).  However, a single daily dose of 
AP5 apparently was sufficient to disrupt the function of those NMDA receptors with a 
gain of function due to gestational exposure to Nic+EtOH.  However, the mechanism 
underlying this susceptibility to AP5 is not understood. 
 
In summary, adolescent offspring exposed to Nic+EtOH during gestation show markedly 
increased vulnerability to become dependent on nicotine. These offspring acquire 
significantly higher levels of nicotine SA during adolescence. This reflects the enhanced 
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function of a subpopulation of VTA NMDA receptors that confer greater nicotine-
induced DA release in NAcc. 
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CHAPTER 5.    CONCLUSIONS 
 
 
Nicotine and ethanol each exert effects on the developing brain that result in long-lasting 
behavioral alterations.  Our full-gestational exposure to Nic+EtOH results in an enhanced 
acquisition to nicotine SA in both adult and adolescent offspring compared to PF 
controls.  We have shown that the model of gestational drug exposure is responsible for 
the alteration in SA behavior, not a change in maternal-offspring interactions. The 
enhancement of nicotine SA by Nic+EtOH offspring can be reversed with the treatment 
of a GABA-B receptor agonist or a NMDA receptor antagonist.  Nic+EtOH offspring 
display an alteration in the modulation of VTA DA neurons in response to nicotine by 
GABA, this is not seen in PF offspring or offspring with exposure to Nic, or EtOH alone.  
The resulting increased DA response to nicotine in the NAcc is also only seen in 
Nic+EtOH offspring, which indicates that the gestational exposure to both drugs is 
necessary to produce the enhanced SA behavior. The Nic+EtOH offspring display a 
hypersensitivity to intra-VTA NMDA compared with PF and a greater reduction of 
GABA release in response to 30µg/kg nicotine i.v.  Offspring born with gestational 
exposure do not differ in basic physical characteristics (growth curve and birth 
parameters: birth weight (PN1), volume displacement, crown-rump length, and brain 
weight) from PF offspring.  Taken together these results indicate that the enhanced 
acquisition of nicotine SA as seen in Nic+EtOH offspring is at least, in part, due to a 
change in modulation of VTA DA neurons by glutamate and GABA in the 
mesocorticolimbic pathway.   
 
The experiments show that intra-VTA microinjection of either baclofen or AP-5 was able 
to disrupt the Nic+EtOH offspring SA behavior and alter responding for nicotine to PF 
levels.  It should be noted that the microinjection was not able to block the acquisition of 
nicotine of these offspring or the PF offspring.  Previous studies have shown that both 
microinjection of AP5 (Zellner et al. 2009) and baclofen (Paterson et al. 2004) was able 
to disrupt learning behavior in untreated animals.  The difference in the results could be 
due to the dose of the microinjections or possibly a result of the use of our 23-hour SA 
model because baclofen or AP-5 would not be in the animals system for the entire 
session.  However, adding a second microinjection would disrupt the SA session and 
would add another variable to which there would be no control. 
 
It is important to note that the VTA as part of the mesocorticolimbic pathway is a 
complex area containing inputs that were not mentioned in these experiments that 
include: Acetylcholine (ACh), Noradrenaline, and Serotonin (5-HT) (Adell and Artigas 
2004).  In addition the VTA has DA neurons that project to the prefrontal cortex.  Each of 
the experiments completed focused on only one VTA modulator in the mesocorticolimbic 
pathway.   
 
Further investigation is needed to determine the full extent of alteration in the VTA as 
part of the mesocorticolimbic pathway of Nic+EtOH offspring.  One possible alteration 
to be examined is serotonin (5-HT) from the midbrain raphe nuclei (Adell and Artigas 
2004).  Serotonin neurons are located on both dopamine and GABA neurons and there 
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are several 5-HT receptor subtypes in the VTA (Adell and Artigas 2004).  For example, 
the 5-HT1A receptor subunit exerts biphasic control in the VTA, increasing dopamine 
release at low doses, while at high doses dopamine release is reduced (Adell and Artigas 
2004).  
 
Prenatal exposure to nicotine has been indicated in changes in the 5-HT system whose 
interactions might indicate predisposition of cognitive impairments (Muneoka et al. 
1997).  The prenatal exposure produces long-lasting changes in 5-HT synaptic function, 
these changes have demonstrated a relationship between maternal smoking and nicotine 
self-administration by offspring (Slotkin et al. 2007).  The study by Slotkin et al. (2007) 
also showed that the initial response to nicotine produces adjustments in baseline levels 
of the 5-HT system.  Prenatal nicotine has also been identified in a decrease in 5-HT 
transporters (Xu et al. 2001).  However, the study also found, upon examination of cell 
bodies the marker for transporter synthesis was increased in the brainstem of animals 
with exposure to nicotine indicating regrowth in response to neural damage (Xu et al. 
2001).   In addition, prenatal ethanol exposure in mice has been shown to hinder the 
development of 5-HT neurons causing them to appear abnormal (Zhou et al. 2001).  
Studies in both mice and rats have demonstrated a reduction in 5-HT neurons in the 
dorsal raphe of offspring with prenatal exposure to ethanol (Sari and Zhou 2004; 
Tajuddin and Druse 2001).   
 
Gestational drug exposure (to either nicotine or EtOH) in animal models has previously 
shown changes in 5-HT.  Therefore, possible changes 5-HT input of VTA function as 
part of the mesocorticolimbic pathway in Nic+EtOH offspring should be examined. 
Another possible contributor to the enhancement in Nic+EtOH SA behavior is ACh.  
Both DA and GABA neurons in the VTA  are modulated by ACh with inputs from PPTg 
and LTDg (Tolu et al. 2013).  It has been shown that intra-VTA methyllycaconitine 
(MLA), an α7 nicotinic acetylcholine (nACh) receptor antagonist was able to block the 
increased NAcc DA release (Schilstrom et al. 1998).  A study has shown that α7 nACh 
receptors are located on glutamatergic axon terminals in the VTA (Jones and Wonnacott 
2004).  The placement of the nACh receptors enhances the release of glutamate onto 
VTA DA neurons (Jones and Wonnacott 2004). 
 
The understanding of ACh and 5-HT in the mesocorticolimbic pathway may provide 
insight into the effectiveness of current smoking cessation treatments.  One of the popular 
treatments is varenicline, acting as a partial nACh receptor agonist and by blocking nACh 
receptors (Polosa and Benowitz 2011; Syed and Chaudhari 2013).  Varenicline is also an 
agonist for the 5-HT3 receptors (Lummis et al. 2011).  Other smoking cessation 
treatments include nicotine replacement therapy (NRT) and the use of NRT with 
buproprion, an antidepressant (Syed and Chaudhari 2013).  However, the mechanism of 
action for buproprion is unknown (Syed and Chaudhari 2013). 
 
The co-morbid effects to gestational nicotine and ethanol investigated using our 
gestational model provide some insight into the possible alteration of mesocorticolimbic 
mechanisms responsible for the increased correlation between maternal smoking as an 
indicator of their children smoking (Buka et al. 2003).  Our results also show that the 
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increase in nicotine intake is present in both adolescent and adult animals, suggesting that 
the alteration in the mesocorticolimbic pathway involved in drug reward is long-lasting.    
It has been shown that most smokers try their first cigarette before the age of 18 (Kandel 
et al. 2007) and they tend to continue to smoke into adulthood (Colby et al. 2000).  In 
addition, those who begin to smoke as an adolescent require less exposure to cigarettes 
before showing signs of dependence when compared to adult smokers (Colby et al. 
2000).  
 
Epidemiological studies have shown that children of smoking mothers are more likely to 
experiment early with cigarettes (Cornelius et al. 2000).  The early availability of 
cigarettes due to legal purchase at age 18 is found to possibly lead to the use of other 
drugs of abuse (Myers and Kelly 2006).  The experiments completed provide some 
insight into the deleterious effects of gestational Nic+EtOH exposure and how they 
resulted in the enhanced nicotine SA.  It is possible that there is subset of the population 
that is more likely to use drugs of abuse because of alterations in their mesocorticolimbic 
reward pathway because of their gestational drug exposure.  Documentation of 
gestational drug exposure and the outcomes of the children, specifically drug use, that 
could provide much needed information on whether this behavioral phenomenon 
observed in our experiments is present in the human population. 
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